BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047. [PMID: 10744089 DOI: 10.1016/s0140-6736(00)02034-1] [Cited by in Crossref: 2288] [Cited by in F6Publishing: 663] [Article Influence: 109.0] [Reference Citation Analysis]
Number Citing Articles
1 Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S3-17. [PMID: 20680105 DOI: 10.3747/co.v17is1.616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
2 Ghiringhelli F, Richard C, Chevrier S, Végran F, Boidot R. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. World J Gastroenterol 2016; 22(48): 10680-10686 [PMID: 28082821 DOI: 10.3748/wjg.v22.i48.10680] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
3 Carethers JM. Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap Adv Gastroenterol 2008;1:33-42. [PMID: 21180512 DOI: 10.1177/1756283X08093607] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
4 Budithi A, Su S, Kirshtein A, Shahriyari L. Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. Cancers (Basel) 2021;13:2632. [PMID: 34071939 DOI: 10.3390/cancers13112632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer. 2011;105:53-57. [PMID: 21654688 DOI: 10.1038/bjc.2011.206] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 7.4] [Reference Citation Analysis]
6 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Sakuyama N, Sato T, Kishine K, Abe Y, Nagaoka I. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett. 2019;17:1842-1850. [PMID: 30675246 DOI: 10.3892/ol.2017.6960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Wang P, Chen Z, Huang WX, Liu LM. Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: A literature review of randomized control trials. World J Gastroenterol 2005; 11(25): 3817-3822 [PMID: 15991275 DOI: 10.3748/wjg.v11.i25.3817] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
8 García-Carbonero R, Gómez España MA, Casado Sáenz E, Alonso Orduña V, Cervantes Ruipérez A, Gallego Plazas J, García Alfonso P, Juez Martel I, González Flores E, Lomas Garrido M, Isla Casado D; SEOM (Spanish Society for Medical Oncology). SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clin Transl Oncol 2010;12:729-34. [PMID: 20974564 DOI: 10.1007/s12094-010-0587-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
9 Herbrand AK, Schmitt AM, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord KA, Novak U, Sricharoenchai S, Hemkens LG, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019;4:e000596. [PMID: 31803503 DOI: 10.1136/esmoopen-2019-000596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cercek A, Gendel V, Jabbour S, Moore D, Chen C, Nosher J, Capanu M, Chou JF, Boucher T, Kemeny N, Carpizo DR. A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases. Curr Treat Options Oncol 2017;18:42. [PMID: 28608276 DOI: 10.1007/s11864-017-0481-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015;15:496. [PMID: 26141683 DOI: 10.1186/s12885-015-1503-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kotake M, Aoyama T, Munemoto Y, Doden K, Kataoka M, Kobayashi K, Nishimura G, Fujita H, Nakamura K, Takehara A, Tanaka C, Sakamoto J, Nagata N, Oba K, Kondo K. Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial). Oncol Lett 2017;13:747-53. [PMID: 28356954 DOI: 10.3892/ol.2016.5505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
13 Li M, Wang Z, Guo J, Liu J, Li C, Liu L, Shi H, Liu L, Li H, Xie C, Zhang X, Sun W, Fang S, Bi X. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther 2014;7:1653-61. [PMID: 25285015 DOI: 10.2147/OTT.S67867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
14 Van den Brande J, Schöffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Köhler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003;88:648-53. [PMID: 12659110 DOI: 10.1038/sj.bjc.6600781] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
15 de la Cueva A, Ramírez de Molina A, Alvarez-Ayerza N, Ramos MA, Cebrián A, Del Pulgar TG, Lacal JC. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One. 2013;8:e64961. [PMID: 23762272 DOI: 10.1371/journal.pone.0064961] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
16 Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, Giovannini I, Barone C. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11:318-324. [PMID: 17458605 DOI: 10.1007/s11605-006-0070-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
17 Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK, Al-Kuraya KS. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 2011;178:537-47. [PMID: 21281787 DOI: 10.1016/j.ajpath.2010.10.020] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 9.1] [Reference Citation Analysis]
18 Saif MW, Sellers S, Diasio RB, Douillard JY. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anticancer Drugs 2010;21:716-23. [PMID: 20581657 DOI: 10.1097/CAD.0b013e32833cb658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Yamane H, Matsubara M, Umemura S, Suwaki T, Kamei H, Takigawa N, Kiura K, Tanimoto M. Variant angina pectoris associated with FOLFOX4 therapy. World J Gastrointest Oncol 2011; 3(11): 165-168 [PMID: 22110843 DOI: 10.4251/wjgo.v3.i11.165] [Reference Citation Analysis]
20 Baba H, Hayashi N, Emi Y, Kakeji Y, Egashira A, Oki E, Shirabe K, Toyama T, Ohga T, Yamamoto M, Hasegawa H, Kohakura F, Higashi H, Niwa K, Fujita F, Ogata Y, Kohnoe S, Inomata M, Samura H, Tokunaga S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. Surg Today 2011;41:1610-6. [PMID: 21969193 DOI: 10.1007/s00595-011-4589-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 2009;9:156. [PMID: 19457245 DOI: 10.1186/1471-2407-9-156] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
22 Kim AY, Kwak JH, Je NK, Lee YH, Jung YS. Epithelial-mesenchymal Transition is Associated with Acquired Resistance to 5-Fluorocuracil in HT-29 Colon Cancer Cells. Toxicol Res 2015;31:151-6. [PMID: 26191381 DOI: 10.5487/TR.2015.31.2.151] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
23 Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 2007;97:1469-74. [PMID: 18040272 DOI: 10.1038/sj.bjc.6604053] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
24 Murono K, Kawai K, Kazama S, Tsuno NH, Sunami E, Kitayama J, Watanabe T. Colorectal cancer with multiple metachronous metastasis achieving complete remission 14 years after surgical resection: report of a case. Int Surg 2013;98:49-54. [PMID: 23438276 DOI: 10.9738/CC172.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 2015;16:1726-37. [PMID: 26553611 DOI: 10.1080/15384047.2015.1113356] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 9.2] [Reference Citation Analysis]
26 Merkel S, Schellerer VS, Wein A, Semrau S, Geppert C, Göhl J, Hohenberger W, Weber K, Grützmann R. The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection. Int J Colorectal Dis 2018;33:1215-23. [PMID: 29915904 DOI: 10.1007/s00384-018-3098-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008;8:120. [PMID: 18439246 DOI: 10.1186/1471-2407-8-120] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
28 Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2013;17:533-46, vii. [PMID: 24099016 DOI: 10.1016/j.cld.2013.07.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
29 Baek SK, Lee KT, Bae SB, Lee SC. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean J Intern Med 2019;34:1188-96. [PMID: 31346151 DOI: 10.3904/kjim.2019.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res 2013;19:2646-56. [PMID: 23669424 DOI: 10.1158/1078-0432.CCR-12-2939] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
31 Kuehr T, Ruff P, Rapoport BL, Falk S, Daniel F, Jacobs C, Davidson N, Thaler J, Boussard B, Carmichael J. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer 2004;4:36. [PMID: 15257756 DOI: 10.1186/1471-2407-4-36] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
32 Aung KL, Stockley TL, Serra S, Kamel-Reid S, Bedard PL, Siu LL. Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Cold Spring Harb Mol Case Stud 2016;2:a001016. [PMID: 27626067 DOI: 10.1101/mcs.a001016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
33 Yamamoto T, Uemura K, Moriyama K, Mitamura K, Taga A. Inhibitory effect of maple syrup on the cell growth and invasion of human colorectal cancer cells. Oncol Rep 2015;33:1579-84. [PMID: 25647359 DOI: 10.3892/or.2015.3777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
34 Qutub RM, Al-Ghafari AB, Al Doghaither HA, Omar UM, Ghulam JM. Increased expressions of cellular ATP-binding cassette transporters may be a promising diagnostic marker for colorectal cancer. Saudi Med J 2020;41:834-40. [PMID: 32789424 DOI: 10.15537/smj.2020.8.25187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Abdirahman SM, Christie M, Preaudet A, Burstroem MCU, Mouradov D, Lee B, Sieber OM, Putoczki TL. A Biobank of Colorectal Cancer Patient-Derived Xenografts. Cancers (Basel) 2020;12:E2340. [PMID: 32825052 DOI: 10.3390/cancers12092340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Xiao XG, Xia S, Zou M, Mei Q, Zhou L, Wang SJ, Chen Y. The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Onco Targets Ther 2015;8:3575-83. [PMID: 26664141 DOI: 10.2147/OTT.S95149] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
37 Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, Gordon MA, Lenz HJ, Van Schaeybroeck S, Longley DB. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol Cancer Ther. 2012;11:119-131. [PMID: 22027693 DOI: 10.1158/1535-7163.MCT-11-0510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
38 Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2011;10:210-6. [PMID: 21855046 DOI: 10.1016/j.clcc.2011.03.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
39 Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9. [PMID: 19707427 DOI: 10.2147/btt.s1519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
40 Gan S, Wilson K, Hollington P. Surveillance of patients following surgery with curative intent for colorectal cancer. World J Gastroenterol 2007; 13(28): 3816-3823 [PMID: 17657835 DOI: 10.3748/wjg.v13.i28.3816] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
41 Kim YW, Kim IY. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol 2013;29:44-54. [PMID: 23700570 DOI: 10.3393/ac.2013.29.2.44] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
42 Chang CL, Yuan KS, Wu ATH, Wu SY. Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. Cancers (Basel) 2019;11:E2003. [PMID: 31842371 DOI: 10.3390/cancers11122003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
43 Sanogo S, Silimbani P, Gaggeri R, Masini C. Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/polyamide infusion bags. J Oncol Pharm Pract 2021;27:288-96. [PMID: 32299315 DOI: 10.1177/1078155220918025] [Reference Citation Analysis]
44 Yun CW, Lee JH, Go G, Jeon J, Yoon S, Lee SH. Prion Protein of Extracellular Vesicle Regulates the Progression of Colorectal Cancer. Cancers (Basel) 2021;13:2144. [PMID: 33946823 DOI: 10.3390/cancers13092144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemother Pharmacol 2019;83:123-9. [PMID: 30377777 DOI: 10.1007/s00280-018-3711-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
46 Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J, Segura A, Gómez-Codina J. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol 2006;23:347-57. [PMID: 17018892 DOI: 10.1385/mo:23:3:347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
47 Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19:1206-1213. [PMID: 19137310 DOI: 10.1007/s00330-008-1258-5] [Cited by in Crossref: 168] [Cited by in F6Publishing: 157] [Article Influence: 14.0] [Reference Citation Analysis]
48 Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052-61; discussion 1061-4. [PMID: 15570210 DOI: 10.1097/01.sla.0000145964.08365.01] [Cited by in Crossref: 798] [Cited by in F6Publishing: 532] [Article Influence: 49.9] [Reference Citation Analysis]
49 Kciuk M, Marciniak B, Kontek R. Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. Int J Mol Sci 2020;21:E4919. [PMID: 32664667 DOI: 10.3390/ijms21144919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
50 Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 2006;95:1637-41. [PMID: 17106441 DOI: 10.1038/sj.bjc.6603468] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
51 Johnston PG. Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era. Oncologist 2014;19:568-73. [PMID: 24718513 DOI: 10.1634/theoncologist.2014-038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
52 Sobrero A, Guglielmi A, Cirillo M, Recaldin E, Frassineti GL, Aschele C, Ravaioli A, Testore P, Caroti C, Gallo L, Pessi MA, Cortesi E, Turci D, Grossi F, Labianca R. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. Br J Cancer 2001;84:1023-8. [PMID: 11308248 DOI: 10.1054/bjoc.2001.1732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
53 Carnaghi C, Santoro A, Rimassa L, Doci R, Rosati R, Pedicini V, Gullo G, Zuradelli M, Abbadessa G, Morenghi E, Marcon I, Garassino I. The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. Invest New Drugs 2007;25:479-85. [PMID: 17492399 DOI: 10.1007/s10637-007-9048-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
54 Wang Z, Dai WP, Zang YS. Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report. Onco Targets Ther. 2019;12:443-447. [PMID: 30662270 DOI: 10.2147/ott.s180845] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
55 Patel GS, Jain K, Kumar R, Strickland AH, Pellegrini L, Slavotinek J, Eaton M, McLeay W, Price T, Ly M, Ullah S, Koczwara B, Kichenadasse G, Karapetis CS. Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Support Care Cancer 2014;22:121-8. [PMID: 24005884 DOI: 10.1007/s00520-013-1941-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
56 Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007;96:206-12. [PMID: 17242694 DOI: 10.1038/sj.bjc.6603561] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
57 Bae SB, Lee NS, Kim HJ, Kim KH, Kim HJ, Kim CK, Lee KT, Park SK, Won JH, Hong DS, Park HS. A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer. Cancer Res Treat 2006;38:72-7. [PMID: 19771263 DOI: 10.4143/crt.2006.38.2.72] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
58 Yang XC, Tu CX, Luo PH, Zhu H, Zhu DF, Wu HH, Zhou XL, Lu W, He QJ, Yang B. Antimetastatic activity of MONCPT in preclinical melanoma mice model. Invest New Drugs 2010;28:800-11. [PMID: 19789842 DOI: 10.1007/s10637-009-9323-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
59 Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009;14:4517-45. [PMID: 19924084 DOI: 10.3390/molecules14114517] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 5.7] [Reference Citation Analysis]
60 Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Invest New Drugs 2014;32:561-8. [PMID: 24573743 DOI: 10.1007/s10637-014-0075-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 Fernandez Montes A, Vazquez Rivera F, Martinez Lago N, Covela Rúa M, Cousillas Castiñeiras A, Gonzalez Villarroel P, de la Cámara Gómez J, Méndez Méndez JC, Salgado Fernández M, Candamio Folgar S, Reboredo López M, Carmona Campos M, Gallardo Martín E, Jorge Fernández M, Pellón Augusto ML, París Bouzas L, García Gómez J. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clin Transl Oncol 2020;22:351-9. [PMID: 31073972 DOI: 10.1007/s12094-019-02130-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
62 McCulloch M, Ly H, Broffman M, See C, Clemons J, Chang R. Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer: A Quality-Adjusted Meta-Analysis of Randomized Controlled Trials. Integr Cancer Ther 2016;15:285-307. [PMID: 27151587 DOI: 10.1177/1534735416638738] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
63 Honecker F, Köhne CH, Bokemeyer C. Colorectal cancer in the elderly: is palliative chemotherapy of value? Drugs Aging 2003;20:1-11. [PMID: 12513112 DOI: 10.2165/00002512-200320010-00001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
64 Mahteme H, Hansson J, Berglund A, Påhlman L, Glimelius B, Nygren P, Graf W. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 2004;90:403-7. [PMID: 14735184 DOI: 10.1038/sj.bjc.6601586] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
65 Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, Miller F, Ryu RK, Ibrahim S, Sato KT. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci. 2008;53:2556-2563. [PMID: 18231857 DOI: 10.1007/s10620-007-0148-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 6.8] [Reference Citation Analysis]
66 Sun J, Ren Z, Sun X, Hou H, Li K, Ge Q. Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis. Oncotarget. 2017;8:39673-39682. [PMID: 28562333 DOI: 10.18632/oncotarget.17784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh T. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 2013;139:367-78. [PMID: 23099994 DOI: 10.1007/s00432-012-1340-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
68 Hsu CW, King TM, Lin CH, Wang HT, Ou WC, Wang JH. Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis. Int J Colorectal Dis 2009;24:377-83. [PMID: 19116722 DOI: 10.1007/s00384-008-0621-y] [Reference Citation Analysis]
69 Cisterna BA, Kamaly N, Choi WI, Tavakkoli A, Farokhzad OC, Vilos C. Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) 2016;11:2443-56. [PMID: 27529192 DOI: 10.2217/nnm-2016-0194] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 13.2] [Reference Citation Analysis]
70 Kim YW, Kim IY. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol 2013;29:44-54. [PMID: 23700570 DOI: 10.3393/ac.2013.29.2.44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29:1083-1090. [PMID: 21263087 DOI: 10.1200/jco.2010.32.6132] [Cited by in Crossref: 256] [Cited by in F6Publishing: 95] [Article Influence: 25.6] [Reference Citation Analysis]
72 Huber HJ, McKiernan RG, Prehn JH. Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches? J Mol Med (Berl) 2014;92:227-37. [PMID: 24477766 DOI: 10.1007/s00109-014-1126-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
73 Saif MW. Targeting cancers in the gastrointestinal tract: role of capecitabine. Onco Targets Ther 2009;2:29-41. [PMID: 20616892 DOI: 10.2147/ott.s3469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
74 Tsushima T, Taguri M, Honma Y, Takahashi H, Ueda S, Nishina T, Kawai H, Kato S, Suenaga M, Tamura F. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist. 2012;17:1163-1170. [PMID: 22622149 DOI: 10.1634/theoncologist.2012-0079] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.2] [Reference Citation Analysis]
75 Stintzing S. Management of colorectal cancer. F1000Prime Rep 2014;6:108. [PMID: 25580262 DOI: 10.12703/P6-108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
76 Köhne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003;89:997-1001. [PMID: 12966415 DOI: 10.1038/sj.bjc.6601226] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.0] [Reference Citation Analysis]
77 Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer. 2013;13:67. [PMID: 23391248 DOI: 10.1186/1471-2407-13-67] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
78 Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75-89. [PMID: 22423266 DOI: 10.1177/1758834011431592] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
79 Jeon EK, Hong SH, Kim TH, Jung SE, Park JC, Won HS, Ko YH, Rho SY, Hong YS. Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. Cancer Res Treat 2011;43:148-53. [PMID: 22022291 DOI: 10.4143/crt.2011.43.3.148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
80 Kurokawa K, Tanahashi T, Iima T, Yamamoto Y, Akaike Y, Nishida K, Masuda K, Kuwano Y, Murakami Y, Fukushima M. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol. 2012;47:883-895. [PMID: 22382630 DOI: 10.1007/s00535-012-0547-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 7.1] [Reference Citation Analysis]
81 Prat A, Casado E, Cortés J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007; 13(44): 5857-5866 [PMID: 17990351 DOI: 10.3748/wjg.v13.i44.5857] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
82 Uemura M, Kim HM, Hata T, Sakata K, Okuyama M, Takemoto H, Fujii H, Fukuzaki T, Morita T, Hata T, Takemasa I, Satoh T, Mizushima T, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer. Mol Clin Oncol 2016;5:375-9. [PMID: 27446583 DOI: 10.3892/mco.2016.938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
83 McNair AG, Macefield RC, Blencowe NS, Brookes ST, Blazeby JM. 'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic Review. PLoS One 2016;11:e0160998. [PMID: 27571514 DOI: 10.1371/journal.pone.0160998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
84 Zhu Y, Wang G, Li X, Wang T, Weng M, Zhang Y. Knockout of SIRT4 decreases chemosensitivity to 5-FU in colorectal cancer cells. Oncol Lett 2018;16:1675-81. [PMID: 30008852 DOI: 10.3892/ol.2018.8850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
85 Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs 2013;31:845-57. [PMID: 23299388 DOI: 10.1007/s10637-012-9914-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
86 Hiraoka K, Kimura T, Logg CR, Tai CK, Haga K, Lawson GW, Kasahara N. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 2007;67:5345-53. [PMID: 17545615 DOI: 10.1158/0008-5472.CAN-06-4673] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
87 Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432. [PMID: 20003271 DOI: 10.1186/1471-2407-9-432] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 8.7] [Reference Citation Analysis]
88 Engelmann BE, Loft A, Kjær A, Nielsen HJ, Gerds TA, Benzon EV, Brünner N, Christensen IJ, Hansson SH, Holländer NH, Kristensen MH, Löfgren J, Markova E, Sloth C, Højgaard L. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer. Oncologist 2014;19:164-72. [PMID: 24451199 DOI: 10.1634/theoncologist.2013-0229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
89 Horiguchi H, Endo M, Miyamoto Y, Sakamoto Y, Odagiri H, Masuda T, Kadomatsu T, Tanoue H, Motokawa I, Terada K, Morioka MS, Manabe I, Baba H, Oike Y. Angiopoietin-like protein 2 renders colorectal cancer cells resistant to chemotherapy by activating spleen tyrosine kinase-phosphoinositide 3-kinase-dependent anti-apoptotic signaling. Cancer Sci 2014;105:1550-9. [PMID: 25287946 DOI: 10.1111/cas.12554] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
90 Leonard P, Seymour MT, James R, Hochhauser D, Ledermann JA. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 2002;87:1216-20. [PMID: 12439708 DOI: 10.1038/sj.bjc.6600641] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
91 Lungoci C, Mironiuc AI, Muntean V, Oniu T, Leebmann H, Mayr M, Piso P. Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol 2016; 8(1): 67-82 [PMID: 26798438 DOI: 10.4251/wjgo.v8.i1.67] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
92 Degeling K, Wong HL, Koffijberg H, Jalali A, Shapiro J, Kosmider S, Wong R, Lee B, Burge M, Tie J, Yip D, Nott L, Khattak A, Lim S, Caird S, Gibbs P, IJzerman M. Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. Pharmacoeconomics 2020;38:1263-75. [PMID: 32803720 DOI: 10.1007/s40273-020-00951-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Han W, Xie B, Li Y, Shi L, Wan J, Chen X, Wang H. Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer. Theranostics 2019;9:7458-73. [PMID: 31695780 DOI: 10.7150/thno.38081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
94 Wang L, Chan CEL, Wong AL, Wong FC, Lim SW, Chinnathambi A, Alharbi SA, Lee LS, Soo R, Yong WP, Lee SC, Ho PC, Sethi G, Goh BC. Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1. Oncotarget 2017;8:41572-81. [PMID: 28157715 DOI: 10.18632/oncotarget.15017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
95 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 203] [Cited by in F6Publishing: 194] [Article Influence: 40.6] [Reference Citation Analysis]
96 Xu W, Kuang M, Gong Y, Cao C, Chen J, Tang C. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. Onco Targets Ther 2016;9:4833-42. [PMID: 27536147 DOI: 10.2147/OTT.S104981] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
97 Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis 2019;40:422-31. [PMID: 30590435 DOI: 10.1093/carcin/bgy186] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
98 Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, Schroeder M, Klein O, Höhler T, Galle PR, Heike M, Moehler M. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 2004;4:38. [PMID: 15265233 DOI: 10.1186/1471-2407-4-38] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
99 Jian YS, Chen CW, Lin CA, Yu HP, Lin HY, Liao MY, Wu SH, Lin YF, Lai PS. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. Int J Nanomedicine 2017;12:2315-33. [PMID: 28392690 DOI: 10.2147/IJN.S120847] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 5.3] [Reference Citation Analysis]
100 Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer 2019;1871:434-54. [PMID: 31034926 DOI: 10.1016/j.bbcan.2019.04.005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 33.5] [Reference Citation Analysis]
101 Aparo S, Goel S. Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol 2012;83:47-58. [PMID: 21944740 DOI: 10.1016/j.critrevonc.2011.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
102 Li X, Liu S, Gu H, Wang D. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. J Cancer Res Clin Oncol 2012;138:1963-9. [PMID: 22763646 DOI: 10.1007/s00432-012-1278-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
103 Barreto R, Kitase Y, Matsumoto T, Pin F, Colston KC, Couch KE, O'Connell TM, Couch ME, Bonewald LF, Bonetto A. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci Rep 2017;7:14470. [PMID: 29089584 DOI: 10.1038/s41598-017-15040-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
104 Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang YW, Yeh CG, Chen LT. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC Cancer 2016;16:907. [PMID: 27871319 DOI: 10.1186/s12885-016-2933-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
105 Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, Myers JN. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006;12:600-7. [PMID: 16428506 DOI: 10.1158/1078-0432.CCR-05-1325] [Cited by in Crossref: 63] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
106 Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut 2005;54:1194-202. [PMID: 16009693 DOI: 10.1136/gut.2004.062745] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
107 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
108 Primrose JN. Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut 2002;50:1-5. [PMID: 11772955 DOI: 10.1136/gut.50.1.1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
109 Braun MS, Adab F, Bradley C, McAdam K, Thomas G, Wadd NJ, Rea D, Philips R, Twelves C, Bozzino J, MacMillan C, Saunders MP, Counsell R, Anderson H, McDonald A, Stewart J, Robinson A, Davies S, Richards FJ, Seymour MT. Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. Br J Cancer 2003;89:1155-8. [PMID: 14520437 DOI: 10.1038/sj.bjc.6601237] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
110 Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs 2007;67:1851-67. [PMID: 17722954 DOI: 10.2165/00003495-200767130-00004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
111 Vargas GM, Parmar AD, Sheffield KM, Tamirisa NP, Brown KM, Riall TS. Impact of liver-directed therapy in colorectal cancer liver metastases. J Surg Res 2014;191:42-50. [PMID: 24990539 DOI: 10.1016/j.jss.2014.05.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
112 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 0.4] [Reference Citation Analysis]
113 Russell S, Wojtkowiak J, Neilson A, Gillies RJ. Metabolic Profiling of healthy and cancerous tissues in 2D and 3D. Sci Rep 2017;7:15285. [PMID: 29127321 DOI: 10.1038/s41598-017-15325-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
114 Stevenson L, Allen WL, Proutski I, Stewart G, Johnston L, McCloskey K, Wilson PM, Longley DB, Johnston PG. Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. PLoS One 2011;6:e20276. [PMID: 21629658 DOI: 10.1371/journal.pone.0020276] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
115 Rashedi J, Ghorbani Haghjo A, Mesgari Abbasi M, Dastranj Tabrizi A, Yaqoubi S, Sanajou D, Ashrafi Jigheh Z, Namvaran A, Mohammadi A, Mohammadi Khoshraj J, Baradaran B. Anti-tumor Effect of Quercetin Loaded Chitosan Nanoparticles on Induced Colon Cancer in Wistar Rats. Adv Pharm Bull 2019;9:409-15. [PMID: 31592135 DOI: 10.15171/apb.2019.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
116 Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J, Shellito P. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 2004;91:839-43. [PMID: 15266319 DOI: 10.1038/sj.bjc.6602039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
117 Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol 2014;45:1381-90. [PMID: 25175642 DOI: 10.3892/ijo.2014.2556] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
118 Fernandez-Plana J, Pericay C, Quintero G, Alonso V, Salud A, Mendez M, Salgado M, Saigi E, Cirera L; ACROSS Study Group. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). BMC Cancer 2014;14:865. [PMID: 25417182 DOI: 10.1186/1471-2407-14-865] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
119 Chen J, Zhong J, Liu Y, Huang Y, Luo F, Zhou Y, Pan X, Cao S, Zhang L, Zhang Y, Wang J. Purified vitexin compound 1, a new neolignan isolated compound, promotes PUMA-dependent apoptosis in colorectal cancer. Cancer Med 2018;7:6158-69. [PMID: 30402948 DOI: 10.1002/cam4.1769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
120 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
121 Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer. 2005;92:820-826. [PMID: 15756252 DOI: 10.1038/sj.bjc.6602354] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
122 Klautke G, Feyerherd P, Ludwig K, Prall F, Foitzik T, Fietkau R. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer. 2005;92:1215-1220. [PMID: 15785742 DOI: 10.1038/sj.bjc.6602492] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
123 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Sakuyama N, Sato T, Kishine K, Abe Y, Nagaoka I. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2019;17:1842-50. [PMID: 30675246 DOI: 10.3892/ol.2018.9805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
124 Zheng Z, Hanna N, Onukwugha E, Reese ES, Seal B, Mullins CD. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Med 2014;3:124-33. [PMID: 24403130 DOI: 10.1002/cam4.176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
125 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF, Helmberger TK. [Developments and perspectives in radioablative techniques]. Radiologe. 2007;47:1083-1088. [PMID: 17943265 DOI: 10.1007/s00117-007-1572-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
126 Yoshioka T, Kato S, Gamoh M, Chiba N, Suzuki T, Sakayori N, Kato S, Shibata H, Shimodaira H, Otsuka K, Kakudo Y, Takahashi S, Ishioka C. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer 2009;101:1972-7. [PMID: 19920821 DOI: 10.1038/sj.bjc.6605432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
127 Kee BK, Morris JS, Slack RS, Crocenzi T, Wong L, Esparaz B, Overman M, Glover K, Jones D, Wen S, Fisch MJ. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer 2015;23:661-70. [PMID: 25160493 DOI: 10.1007/s00520-014-2402-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
128 Pawlik T, Abdalla E, Ellis L, Vauthey J, Curley S. Debunking Dogma: Surgery for Four or More Colorectal Liver Metastases Is Justified. Journal of Gastrointestinal Surgery 2006;10:240-8. [DOI: 10.1016/j.gassur.2005.07.027] [Cited by in Crossref: 74] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
129 Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999. [PMID: 16538219 DOI: 10.1038/sj.bjc.6603033] [Cited by in Crossref: 593] [Cited by in F6Publishing: 523] [Article Influence: 39.5] [Reference Citation Analysis]
130 Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol. 2012;73:776-785. [PMID: 22486600 DOI: 10.1111/j.1365-2125.2011.04141.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
131 Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ. UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol 2009; 15(40): 5058-5066 [PMID: 19859999 DOI: 10.3748/wjg.15.5058] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
132 Noor A, Assiri A, Ayvaz S, Clark C, Dumontier M. Drug-drug interaction discovery and demystification using Semantic Web technologies. J Am Med Inform Assoc 2017;24:556-64. [PMID: 28031284 DOI: 10.1093/jamia/ocw128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
133 McKay A, Kutnikoff T, Taylor M. A cost-utility analysis of treatments for malignant liver tumours: a pilot project. HPB (Oxford) 2007;9:42-51. [PMID: 18333112 DOI: 10.1080/13651820600994541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
134 Han Q, Chen R, Wang F, Chen S, Sun X, Guan X, Yang Y, Peng B, Pan X, Li J, Yi W, Li P, Zhang H, Feng D, Chen A, Li X, Li S, Yin Z. Pre-exposure to 50 Hz-electromagnetic fields enhanced the antiproliferative efficacy of 5-fluorouracil in breast cancer MCF-7 cells. PLoS One 2018;13:e0192888. [PMID: 29617363 DOI: 10.1371/journal.pone.0192888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
135 Tang W, Su G, Li J, Liao J, Chen S, Huang C, Liu F, Chen Q, Ye Y. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo. Int J Oncol 2014;45:995-1010. [PMID: 24968890 DOI: 10.3892/ijo.2014.2513] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
136 Comella P, Farris A, Lorusso V, Palmeri S, Maiorino L, De Lucia L, Buzzi F, Mancarella S, De Vita F, Gambardella A. Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma. Br J Cancer 2003;89:992-6. [PMID: 12966414 DOI: 10.1038/sj.bjc.6601214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
137 Yi L, Lin G, Zhang K, Wang L, Zhang R, Xie J, Li J. Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China. PLoS One 2016;11:e0148081. [PMID: 26820647 DOI: 10.1371/journal.pone.0148081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
138 Tam VC, Rask S, Koru-Sengul T, Dhesy-Thind S. Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer. Curr Oncol 2009;16:13-20. [PMID: 20016742 DOI: 10.3747/co.v16i6.426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
139 Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel) 2021;13:2296. [PMID: 34064974 DOI: 10.3390/cancers13102296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY, Kwon HC, Kang JH. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Invest New Drugs. 2010;28:343-349. [PMID: 19444385 DOI: 10.1007/s10637-009-9265-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
141 Makino H, Uetake H, Danenberg K, Danenberg PV, Sugihara K. Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer. BMC Cancer 2008;8:210. [PMID: 18652704 DOI: 10.1186/1471-2407-8-210] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
142 Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871 [PMID: 25110417 DOI: 10.3748/wjg.v20.i29.9862] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
143 Tsavaris N, Kosmas C, Vadiaka M, Koufos C. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. BMC Cancer 2002;2:2. [PMID: 11860608 DOI: 10.1186/1471-2407-2-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
144 Reidy E, Leonard NA, Treacy O, Ryan AE. A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance. Cancers (Basel) 2021;13:E227. [PMID: 33435170 DOI: 10.3390/cancers13020227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
145 Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, Murai T, Matsuda C, Oba A, Itaya K, Sone T, Yagisawa M, Koike Y, Endo A, Tsukuda Y, Ono Y, Kudo T, Nagasaka A, Nishikawa S, Komatsu Y. A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). Oncologist 2017;22:592-600. [PMID: 28341762 DOI: 10.1634/theoncologist.2016-0308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
146 Robertson DJ, Stukel TA, Gottlieb DJ, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 2009;115:752-9. [PMID: 19130462 DOI: 10.1002/cncr.24081] [Cited by in Crossref: 100] [Cited by in F6Publishing: 87] [Article Influence: 8.3] [Reference Citation Analysis]
147 Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol 2017;9:106-26. [PMID: 28203302 DOI: 10.1177/1758834016676703] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
148 Kobayashi H, Kotake K, Funahashi K, Hase K, Hirata K, Iiai T, Kameoka S, Kanemitsu Y, Maeda K, Murata A. Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol. 2014;49:646-654. [PMID: 23793379 DOI: 10.1007/s00535-013-0820-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
149 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020; 11(10): 761-808 [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
150 Facciorusso A, Del Prete V, Crucinio N, Serviddio G, Vendemiale G, Muscatiello N. Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases. World J Gastroenterol 2016; 22(16): 4211-4218 [PMID: 27122671 DOI: 10.3748/wjg.v22.i16.4211] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
151 Luu C, Arrington AK, Schoellhammer HF, Singh G, Kim J. Targeted therapies in colorectal cancer: surgical considerations. J Gastrointest Oncol 2013;4:328-36. [PMID: 23997944 DOI: 10.3978/j.issn.2078-6891.2013.032] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
152 Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013;7:637-646. [PMID: 23506979 DOI: 10.1016/j.molonc.2013.02.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
153 Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805. [PMID: 16508637 DOI: 10.1038/sj.bjc.6603011] [Cited by in Crossref: 246] [Cited by in F6Publishing: 206] [Article Influence: 16.4] [Reference Citation Analysis]
154 Mabro M, Artru P, André T, Flesch M, Maindrault-Goebel F, Landi B, Lledo G, Plantade A, Louvet C, de Gramont A. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006;94:1287-92. [PMID: 16622455 DOI: 10.1038/sj.bjc.6603095] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
155 Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7(5): 352-369 [PMID: 27777878 DOI: 10.5306/wjco.v7.i5.352] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
156 Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH, Schuff-Werner P. 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J Clin Pathol 2005;58:553-5. [PMID: 15858133 DOI: 10.1136/jcp.2004.022319] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
157 Hu H, Wang M, Guan X, Yuan Z, Liu Z, Zou C, Wang G, Gao X, Wang X. Loss of ABCB4 attenuates the caspase-dependent apoptosis regulating resistance to 5-Fu in colorectal cancer. Biosci Rep 2018;38:BSR20171428. [PMID: 29371412 DOI: 10.1042/BSR20171428] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
158 Pelley RJ. Oxaliplatin: a new agent for colorectal cancer. Curr Oncol Rep 2001;3:147-55. [PMID: 11177747 DOI: 10.1007/s11912-001-0015-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
159 Wilson PM, Fazzone W, LaBonte MJ, Deng J, Neamati N, Ladner RD. Novel opportunities for thymidylate metabolism as a therapeutic target. Mol Cancer Ther 2008;7:3029-37. [PMID: 18790783 DOI: 10.1158/1535-7163.MCT-08-0280] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
160 Watanabe M, Sowa Y, Yogosawa M, Sakai T. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci 2013;104:687-93. [PMID: 23438367 DOI: 10.1111/cas.12139] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
161 Lee MA, Byun JH, Shim BY, Woo IS, Kang JH, Hong YS, Lee KS, Choi MG, Chang SK, Oh ST, Choi SI, Lee DS. Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. Korean J Intern Med 2005;20:205-9. [PMID: 16295778 DOI: 10.3904/kjim.2005.20.3.205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
162 Ou S, Xu R, Li K, Chen Y, Kong Y, Liu H, Li J, Ouyang Y, Yu X. Radiofrequency ablation with systemic chemotherapy in the treatment of colorectal cancer liver metastasis: a 10-year single-center study. Cancer Manag Res 2018;10:5227-37. [PMID: 30464620 DOI: 10.2147/CMAR.S170160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
163 Kari V, Raul SK, Henck JM, Kitz J, Kramer F, Kosinsky RL, Übelmesser N, Mansour WY, Eggert J, Spitzner M, Najafova Z, Bastians H, Grade M, Gaedcke J, Wegwitz F, Johnsen SA. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clin Epigenetics 2019;11:4. [PMID: 30616689 DOI: 10.1186/s13148-018-0601-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
164 Cyjon A, Neuman-Levin M, Rakowsky E, Greif F, Belinky A, Atar E, Hardoff R, Brenner B, Sulkes A. Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy. Br J Cancer 2001;85:504-8. [PMID: 11506487 DOI: 10.1054/bjoc.2001.1972] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
165 Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol 2008;9:357-74. [PMID: 19238551 DOI: 10.1007/s11864-009-0089-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
166 Iles S, Gollins S, Susnerwala S, Haylock B, Myint S, Biswas A, Swindell R, Levine E. Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study. Br J Cancer 2008;98:1210-6. [PMID: 18349840 DOI: 10.1038/sj.bjc.6604292] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
167 Mehta HB, Vargas GM, Adhikari D, Dimou F, Riall TS. Comparative effectiveness of chemotherapy vs resection of the primary tumour as the initial treatment in older patients with Stage IV colorectal cancer. Colorectal Dis 2017;19:O210-8. [PMID: 28304120 DOI: 10.1111/codi.13659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
168 Signore M, Buccarelli M, Pilozzi E, De Luca G, Cappellari M, Fanciulli M, Goeman F, Melucci E, Biffoni M, Ricci-Vitiani L. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget 2016;7:44113-28. [PMID: 27286453 DOI: 10.18632/oncotarget.9859] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
169 Yang S, Alibhai SM, Kennedy ED, El-Sedfy A, Dixon M, Coburn N, Kiss A, Law CH. Optimal management of colorectal liver metastases in older patients: a decision analysis. HPB (Oxford) 2014;16:1031-42. [PMID: 24961482 DOI: 10.1111/hpb.12292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
170 Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010;10:567. [PMID: 20958992 DOI: 10.1186/1471-2407-10-567] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
171 Park EJ, Baek JH, Choi GS, Park WC, Yu CS, Kang SB, Min BS, Kim JH, Kim HR, Lee BH, Oh JH, Jeong SY, Jung M, Ahn JB, Baik SH. The Role of Primary Tumor Resection in Colorectal Cancer Patients with Asymptomatic, Synchronous, Unresectable Metastasis: A Multicenter Randomized Controlled Trial. Cancers (Basel) 2020;12:E2306. [PMID: 32824392 DOI: 10.3390/cancers12082306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
172 Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer 2020;20:687. [PMID: 32703200 DOI: 10.1186/s12885-020-07186-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
173 PelvEx Collaborative . Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). BJS Open 2021;5:zrab029. [PMID: 34089596 DOI: 10.1093/bjsopen/zrab029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Viganò L, Karoui M, Ferrero A, Tayar C, Cherqui D, Capussotti L. Locally advanced mid/low rectal cancer with synchronous liver metastases. World J Surg. 2011;35:2788-2795. [PMID: 21947493 DOI: 10.1007/s00268-011-1272-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
175 Shaojun C, Li H, Haixin H, Guisheng L. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther 2018;19:153-9. [PMID: 29261002 DOI: 10.1080/15384047.2017.1414754] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
176 Yang Y, Han J, Ma Y, Zhang J, Zhang Z, Wang G. Demethylzeylasteral inhibits cell proliferation and enhances cell chemosensitivity to 5-fluorouracil in Colorectal Cancer cells. J Cancer 2020;11:6059-69. [PMID: 32922546 DOI: 10.7150/jca.44375] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 DePrimo SE, Wong LM, Khatry DB, Nicholas SL, Manning WC, Smolich BD, O'Farrell AM, Cherrington JM. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 2003;3:3. [PMID: 12657164 DOI: 10.1186/1471-2407-3-3] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 3.7] [Reference Citation Analysis]
178 Rosati G, Bilancia D. Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer. World J Gastroenterol 2008; 14(12): 1812-1822 [PMID: 18350617 DOI: 10.3748/wjg.14.1812] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
179 Bennouna J, Deslandres M, Senellart H, de Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB, Delord JP. A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Invest New Drugs 2015;33:138-47. [PMID: 25248752 DOI: 10.1007/s10637-014-0142-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
180 Tanaka K, Matsuyama R, Takeda K, Matsuo K, Nagano Y, Endo I. Aggressive liver resection including major-vessel resection for colorectal liver metastases. World J Hepatol 2009; 1(1): 79-89 [PMID: 21160969 DOI: 10.4254/wjh.v1.i1.79] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
181 Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. JCI Insight 2019;5:127552. [PMID: 31237864 DOI: 10.1172/jci.insight.127552] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
182 Tarpgaard LS, Qvortrup C, Nygård SB, Nielsen SL, Andersen DR, Jensen NF, Stenvang J, Detlefsen S, Brünner N, Pfeiffer P. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. BMC Cancer 2016;16:91. [PMID: 26867764 DOI: 10.1186/s12885-016-2124-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
183 Arango D, Mariadason JM, Wilson AJ, Yang W, Corner GA, Nicholas C, Aranes MJ, Augenlicht LH. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003;89:1757-65. [PMID: 14583781 DOI: 10.1038/sj.bjc.6601338] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
184 Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 2013;104:1662-9. [PMID: 24033692 DOI: 10.1111/cas.12283] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
185 Wang X, Sun D, Tai J, Chen S, Yu M, Ren D, Wang L. TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway. J Exp Clin Cancer Res 2018;37:27. [PMID: 29439714 DOI: 10.1186/s13046-018-0683-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
186 Rocha LSDS, Riechelmann RP. Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges. Clinics (Sao Paulo) 2018;73:e542s. [PMID: 30281700 DOI: 10.6061/clinics/2018/e542s] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
187 Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S. Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Invest New Drugs. 2012;30:758-764. [PMID: 21057973 DOI: 10.1007/s10637-010-9575-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
188 Teng CL, Wang CY, Chen YH, Lin CH, Hwang WL. Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study. PLoS One 2015;10:e0135673. [PMID: 26273837 DOI: 10.1371/journal.pone.0135673] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
189 Tohme S, Sukato D, Nace GW, Zajko A, Amesur N, Orons P, Chalhoub D, Marsh JW, Geller DA, Tsung A. Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer. HPB (Oxford) 2014;16:1110-6. [PMID: 25123597 DOI: 10.1111/hpb.12307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
190 Osuga T, Takimoto R, Ono M, Hirakawa M, Yoshida M, Okagawa Y, Uemura N, Arihara Y, Sato Y, Tamura F, Sato T, Iyama S, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J. Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer. J Natl Cancer Inst 2016;108. [PMID: 27075853 DOI: 10.1093/jnci/djw038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
191 Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer. 2006;94:792-797. [PMID: 16508634 DOI: 10.1038/sj.bjc.6603018] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 5.1] [Reference Citation Analysis]
192 Que K, Tong Y, Que G, Li L, Lin H, Huang S, Wang R, Tang L. Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway. Oncol Rep. 2017;38:3376-3386. [PMID: 29039607 DOI: 10.3892/or.2017.6041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
193 Sezer A, Usta U, Cicin I. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol 2009;26:350-7. [PMID: 19067257 DOI: 10.1007/s12032-008-9128-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
194 Xia ZS, Wu D, Zhong W, Lu XJ, Yu T, Chen QK. Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells. Oncol Lett 2017;14:1875-83. [PMID: 28781635 DOI: 10.3892/ol.2017.6361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
195 Ahmad R, Singh JK, Wunnava A, Al-Obeed O, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). Int J Mol Med. 2021;47. [PMID: 33655327 DOI: 10.3892/ijmm.2021.4847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest. 2005;115:1492-1502. [PMID: 15902309 DOI: 10.1172/jci23002] [Cited by in Crossref: 93] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
197 Fujii M, Takayama T, Kochi M. Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial. J Cancer Res Clin Oncol 2008;134:1319-23. [PMID: 18512074 DOI: 10.1007/s00432-008-0417-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
198 Kim MJ, Kim SJ, Park SC, Kim DY, Park JW, Ryoo SB, Jeong SY, Park KJ, Oh HK, Kim DW, Kang SB, Joo JN, Oh JH; SEoul COlorectal Group (SECOG). Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: A propensity score-matched analysis and meta-analysis. Medicine (Baltimore) 2016;95:e4925. [PMID: 27893653 DOI: 10.1097/MD.0000000000004925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
199 Gbolahan O, O'Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol 2019;4:9. [PMID: 30976712 DOI: 10.21037/tgh.2019.01.12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
200 Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol. 2009;6:687-697. [PMID: 19884901 DOI: 10.1038/nrclinonc.2009.165] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
201 Ripley RT, Davis JL, Kemp CD, Steinberg SM, Toomey MA, Avital I. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Trials. 2010;11:62. [PMID: 20500867 DOI: 10.1186/1745-6215-11-62] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
202 Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, Livingston S, Andreyev J. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568-573. [PMID: 12631671 DOI: 10.1136/gut.52.4.568] [Cited by in Crossref: 146] [Cited by in F6Publishing: 128] [Article Influence: 8.1] [Reference Citation Analysis]
203 Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004;91:678-682. [PMID: 15280927 DOI: 10.1038/sj.bjc.6602042] [Cited by in Crossref: 229] [Cited by in F6Publishing: 196] [Article Influence: 13.5] [Reference Citation Analysis]
204 Hofheinz RD, Hartmann JT, Willer A, Oechsle K, Hartung G, Gnad U, Saussele S, Kreil S, Bokemeyer C, Hehlmann R, Hochhaus A. Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Br J Cancer 2004;91:834-8. [PMID: 15238990 DOI: 10.1038/sj.bjc.6602025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
205 Asmis T, Berry S, Cosby R, Chan K, Coburn N, Rother M. Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Curr Oncol. 2014;21:318-328. [PMID: 25489259 DOI: 10.3747/co.21.2146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
206 Ronnekleiv-Kelly SM, Kennedy GD. Management of stage IV rectal cancer: Palliative options. World J Gastroenterol 2011; 17(7): 835-847 [PMID: 21412493 DOI: 10.3748/wjg.v17.i7.835] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
207 Imanishi M, Yamamoto Y, Wang X, Sugaya A, Hirose M, Endo S, Natori Y, Yamato K, Hyodo I. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells. Cancer Sci 2019;110:639-49. [PMID: 30488540 DOI: 10.1111/cas.13893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
208 Brouquet A, Belghiti J. Chemotherapy and its effect on liver hypertrophy: implications for portal vein embolization and resection. Semin Intervent Radiol. 2008;25:162-167. [PMID: 21326557 DOI: 10.1055/s-2008-1076682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
209 Tharin Z, Blanc J, Alaoui IC, Bertaut A, Ghiringhelli F. Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer. J Gastrointest Oncol 2021;12:1509-17. [PMID: 34532106 DOI: 10.21037/jgo-20-593] [Reference Citation Analysis]
210 Shionome Y, Lin WH, Shiao HY, Hsieh HP, Hsu JT, Ouchi T. A novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment. Int J Biol Sci 2013;9:403-11. [PMID: 23678290 DOI: 10.7150/ijbs.5806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
211 Serafino A, Moroni N, Zonfrillo M, Andreola F, Mercuri L, Nicotera G, Nunziata J, Ricci R, Antinori A, Rasi G, Pierimarchi P. WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget 2014;5:978-92. [DOI: 10.18632/oncotarget.1571] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
212 Hwang JE, Shim HJ, Park YK, Cho SH, Bae WK, Kim DE, Kim KK, Chung IJ. Intravenous KITENIN shRNA injection suppresses hepatic metastasis and recurrence of colon cancer in an orthotopic mouse model. J Korean Med Sci 2011;26:1439-45. [PMID: 22065899 DOI: 10.3346/jkms.2011.26.11.1439] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
213 Zhang S, Shi L, Mao D, Peng W, Sheng C, Ding C, Lin F, Lei C, Zhang S. Use of Jianpi Jiedu Herbs in Patients with Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2018;2018:6180810. [PMID: 29619070 DOI: 10.1155/2018/6180810] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
214 Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G, Falcone A. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013;108:2549-56. [PMID: 23703247 DOI: 10.1038/bjc.2013.245] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
215 Zhao C, Zhao Q, Zhang C, Wang G, Yao Y, Huang X, Zhan F, Zhu Y, Shi J, Chen J, Yan F, Zhang Y. miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis. Sci Rep 2017;7:4194. [PMID: 28646148 DOI: 10.1038/s41598-017-04172-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
216 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
217 Bensmaïne MA, Marty M, de Gramont A, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 2001;85:509-17. [PMID: 11506488 DOI: 10.1054/bjoc.2001.1953] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
218 López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010;103:1536-41. [PMID: 20940719 DOI: 10.1038/sj.bjc.6605938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
219 Vonk DT, Hazard LJ. Do all locally advanced rectal cancers require radiation? A review of literature in the modern era. J Gastrointest Oncol. 2010;1:45-54. [PMID: 22811804 DOI: 10.3978/j.issn.2078-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
220 Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 2015;17:1620-7. [PMID: 26541630 DOI: 10.1093/neuonc/nov181] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
221 Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013;24:1560-1567. [PMID: 23493136 DOI: 10.1093/annonc/mdt056] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
222 Tan FH, Putoczki TL, Lou J, Hinde E, Hollande F, Giraud J, Stylli SS, Paradiso L, Zhu HJ, Sieber OM, Luwor RB. Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers (Basel) 2018;10:E526. [PMID: 30572654 DOI: 10.3390/cancers10120526] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
223 Chida K, Kotani D, Nakamura Y, Kawazoe A, Kuboki Y, Shitara K, Kojima T, Taniguchi H, Watanabe J, Endo I, Yoshino T. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. Ther Adv Med Oncol 2021;13:17588359211009143. [PMID: 33959196 DOI: 10.1177/17588359211009143] [Reference Citation Analysis]
224 Waters J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 2001;84:1-7. [PMID: 11139304 DOI: 10.1054/bjoc.2000.1552] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
225 Nishigori H, Ito M, Nishizawa Y, Kohyama A, Koda T, Nakajima K, Nishizawa Y, Kobayashi A, Sugito M, Saito N. Laparoscopic surgery for palliative resection of the primary tumor in incurable stage IV colorectal cancer. Surg Endosc. 2012;26:3201-3206. [PMID: 22648097 DOI: 10.1007/s00464-012-2323-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
226 Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013;13:611. [PMID: 24373251 DOI: 10.1186/1471-2407-13-611] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
227 Neugut AI, Becker DJ, Insel BJ, Hershman DL. Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer. J Oncol Pract 2012;8:156-63. [PMID: 22942809 DOI: 10.1200/JOP.2011.000371] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
228 Tonini G, Calvieri A, Vincenzi B, Santini D. First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. Onco Targets Ther 2009;2:73-82. [PMID: 20616896 DOI: 10.2147/ott.s3465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
229 Yeoh Y, Low TY, Abu N, Lee PY. Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ 2021;9:e12338. [PMID: 34733591 DOI: 10.7717/peerj.12338] [Reference Citation Analysis]
230 Janne d'Othée B, Sofocleous CT, Hanna N, Lewandowski RJ, Soulen MC, Vauthey JN, Cohen SJ, Venook AP, Johnson MS, Kennedy AS, Murthy R, Geschwind JF, Kee ST. Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol 2012;23:153-63. [PMID: 22264550 DOI: 10.1016/j.jvir.2011.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
231 Ohtsukasa S, Okabe S, Yamashita H, Iwai T, Sugihara K. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol. 2003;129:719-726. [PMID: 14564514 DOI: 10.1007/s00432-003-0492-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
232 Allen WL, Turkington RC, Stevenson L, Carson G, Coyle VM, Hector S, Dunne P, Van Schaeybroeck S, Longley DB, Johnston PG. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. Mol Cancer Ther 2012;11:1724-34. [PMID: 22665525 DOI: 10.1158/1535-7163.MCT-12-0207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
233 Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK, Eldon MA, Hoch U, Lockman PR. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer 2015;15:685. [PMID: 26463521 DOI: 10.1186/s12885-015-1672-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
234 Le Roy B, Tixier L, Pereira B, Sauvanet P, Buc E, Pétorin C, Déchelotte P, Pezet D, Balayssac D. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study. PLoS One 2016;11:e0148739. [PMID: 26859833 DOI: 10.1371/journal.pone.0148739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
235 Sharif S, O'Connell MJ, Yothers G, Lopa S, Wolmark N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008;26:956-963. [PMID: 18798075 DOI: 10.1080/07357900802132550] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
236 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207-239. [PMID: 25782566 DOI: 10.1007/s10147-015-0801-z] [Cited by in Crossref: 379] [Cited by in F6Publishing: 363] [Article Influence: 63.2] [Reference Citation Analysis]
237 Lemmens VE, de Haan N, Rutten HJ, Martijn H, Loosveld OJ, Roumen RM, Creemers GJ. Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008. Clin Exp Metastasis 2011;28:283-90. [PMID: 21207120 DOI: 10.1007/s10585-010-9370-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
238 Choi KY, Jeon EJ, Yoon HY, Lee BS, Na JH, Min KH, Kim SY, Myung SJ, Lee S, Chen X, Kwon IC, Choi K, Jeong SY, Kim K, Park JH. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials 2012;33:6186-93. [PMID: 22687759 DOI: 10.1016/j.biomaterials.2012.05.029] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 11.7] [Reference Citation Analysis]
239 Field KM, Kosmider S, Jefford M, Jennens R, Green M, Gibbs P. Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice? J Oncol Pract 2008;4:271-6. [PMID: 20856756 DOI: 10.1200/JOP.0852002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
240 Wang Y, Yi C, Wang Y, Li H, Li B, Wang D, Du J, Liu L, Wang X. Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer. Oncol Lett 2017;14:5743-52. [PMID: 29113203 DOI: 10.3892/ol.2017.6933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
241 Sethi MK, Fanayan S. Mass Spectrometry-Based N-Glycomics of Colorectal Cancer. Int J Mol Sci 2015;16:29278-304. [PMID: 26690136 DOI: 10.3390/ijms161226165] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
242 Bajetta E, Di Bartolomeo M, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Lo Vullo S, Aitini E, Isa L, Barone C. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer. 2007;96:439-444. [PMID: 17245343 DOI: 10.1038/sj.bjc.6603493] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
243 Boueroy P, Hahnvajanawong C, Boonmars T, Saensa-ard S, Wattanawongdon W, Kongsanthia C, Salao K, Wongwajana S, Anantachoke N, Reutrakul V. Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma. Asian Pac J Cancer Prev 2017;18:3343-51. [PMID: 29286229 DOI: 10.22034/APJCP.2017.18.12.3343] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
244 O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381-3388. [PMID: 21788561 DOI: 10.1200/jco.2010.34.3426] [Cited by in Crossref: 269] [Cited by in F6Publishing: 130] [Article Influence: 26.9] [Reference Citation Analysis]
245 Audisio RA, Papamichael D. Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol. 2012;9:716-725. [PMID: 23045000 DOI: 10.1038/nrgastro.2012.196] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
246 Catenacci DV, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin Oncol 2011;38:284-308. [PMID: 21421118 DOI: 10.1053/j.seminoncol.2011.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
247 Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J, Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 2008;99:1607-12. [PMID: 18941461 DOI: 10.1038/sj.bjc.6604691] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
248 Bar-Sela G, Haim N. Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. Med Oncol 2004;21:251-4. [PMID: 15456952 DOI: 10.1385/MO:21:3:251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
249 Moehler M, Eimermacher A, Siebler J, Höhler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer. 2005;92:2122-2128. [PMID: 15942629 DOI: 10.1038/sj.bjc.6602649] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 4.2] [Reference Citation Analysis]
250 Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, Huang X, Hou Y, Zhu D, Zou H, Gu Y, Weng X, Wang Y, Li Y, Wu T, Yao M, Gross I, Gaiddon C, Luo M, Wang J, Meng X. Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene 2020;39:469-85. [PMID: 31597953 DOI: 10.1038/s41388-019-1035-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 18.0] [Reference Citation Analysis]
251 Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, O'Connell MJ, Sargent DJ. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. J Clin Oncol. 2013;31:3656-3663. [PMID: 23980089 DOI: 10.1200/jco.2013.49.4344] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
252 Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist 2019;24:921-32. [PMID: 30552157 DOI: 10.1634/theoncologist.2018-0344] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 8.7] [Reference Citation Analysis]
253 Kim HY, Kim J, Ha Thi HT, Bang OS, Lee WS, Hong S. Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model. BMC Complement Altern Med 2016;16:473. [PMID: 27863496 DOI: 10.1186/s12906-016-1447-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
254 LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011;71:3635-3648. [PMID: 21464044 DOI: 10.1158/0008-5472.can-10-2430] [Cited by in Crossref: 65] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
255 Denecke T, Rühl R, Hildebrandt B, Stelter L, Grieser C, Stiepani H, Werk M, Podrabsky P, Plotkin M, Amthauer H, Ricke J, Lopez Hänninen E. Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques. Eur Radiol 2008;18:892-902. [PMID: 18175122 DOI: 10.1007/s00330-007-0836-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
256 Garambois V, Glaussel F, Foulquier E, Ychou M, Pugnière M, Luo RX, Bezabeh B, Pèlegrin A. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer 2004;4:75. [PMID: 15488142 DOI: 10.1186/1471-2407-4-75] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
257 Sawano T, Shimizu T, Yamada T, Nanashima N, Miura T, Morohashi S, Kudo D, Hui FM, Kijima H, Hakamada K, Tsuchida S. Fatty acid synthase-positive hepatocytes and subsequent steatosis in rat livers by irinotecan. Oncol Rep 2015;33:2151-60. [PMID: 25708528 DOI: 10.3892/or.2015.3814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
258 Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res 2014;20:837-46. [PMID: 24323901 DOI: 10.1158/1078-0432.CCR-13-1854] [Cited by in Crossref: 161] [Cited by in F6Publishing: 108] [Article Influence: 20.1] [Reference Citation Analysis]
259 Ogata Y, Ishibashi N, Yamaguchi K, Uchida S, Kamei H, Nakayama G, Hirakawa H, Tanigawa M, Akagi Y. Preventive effects of amino-acid-rich elemental diet Elental® on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study. Support Care Cancer 2016;24:783-9. [PMID: 26266658 DOI: 10.1007/s00520-015-2844-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
260 Kim B, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer. World J Gastroenterol 2014; 20(15): 4370-4376 [PMID: 24764675 DOI: 10.3748/wjg.v20.i15.4370] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
261 Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009;229:126-44. [PMID: 19426219 DOI: 10.1111/j.1600-065X.2009.00771.x] [Cited by in Crossref: 163] [Cited by in F6Publishing: 104] [Article Influence: 13.6] [Reference Citation Analysis]
262 Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives. J Contemp Brachytherapy 2016;8:251-61. [PMID: 27504135 DOI: 10.5114/jcb.2016.61068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
263 Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med. 2011;9:10. [PMID: 21281463 DOI: 10.1186/1741-7015-9-10] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
264 Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Laan AC, Schott S, Losekoot N, Honeywell RJ, Peters GJ. Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine. Invest New Drugs 2011;29:248-57. [PMID: 19957099 DOI: 10.1007/s10637-009-9353-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
265 Li W, Xu J, Shen L, Liu T, Guo W, Zhang W, Chen Z, Zhu X, Li J. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer 2014;14:986. [PMID: 25527007 DOI: 10.1186/1471-2407-14-986] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
266 Bathe OF, Dowden S, Sutherland F, Dixon E, Butts C, Bigam D, Walley B, Ruether D, Ernst S. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 2004;4:32. [PMID: 15245580 DOI: 10.1186/1471-2407-4-32] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
267 Garufi C, Bria E, Vanni B, Zappalà AM, Sperduti I, Terzoli E. A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Br J Cancer 2003;89:1870-5. [PMID: 14612895 DOI: 10.1038/sj.bjc.6601382] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
268 Miyata Y, Touyama T, Kusumi T, Morita Y, Mizunuma N, Taniguchi F, Manabe M. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. Int J Clin Oncol. 2016;21:696-703. [PMID: 26710796 DOI: 10.1007/s10147-015-0937-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
269 Diaz-Gonzalez JA, Arbea L, Aristu J. Rectal cancer treatment: Improving the picture. World J Gastroenterol 2007; 13(44): 5805-5812 [PMID: 17990346 DOI: 10.3748/wjg.v13.i44.5805] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
270 Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne CH, Seymour MT, de Gramont A, Goldberg RM, Sargent DJ. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol 2011;29:2781-6. [PMID: 21646604 DOI: 10.1200/JCO.2010.33.5281] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
271 El-Rayes BF, Zalupski MM, Manza SG, Rusin B, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Shields AF, Philip PA. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol 2008;61:283-9. [PMID: 17429629 DOI: 10.1007/s00280-007-0472-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
272 Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol 2019;26:S7-S15. [PMID: 31819705 DOI: 10.3747/co.26.5719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
273 Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget 2016;7:9309-21. [PMID: 26824184 DOI: 10.18632/oncotarget.7008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
274 Aranda E, Aparicio J, Alonso V, Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera R, Vieitez JM, Garcia-Carbonero R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol 2015;17:972-81. [PMID: 26669312 DOI: 10.1007/s12094-015-1434-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
275 Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol 2009;63:441-50. [PMID: 18414865 DOI: 10.1007/s00280-008-0754-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
276 Solier S, Zhang YW, Ballestrero A, Pommier Y, Zoppoli G. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. Curr Cancer Drug Targets 2012;12:356-71. [PMID: 22385513 DOI: 10.2174/156800912800190901] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
277 Eisenberger A, Whelan RL, Neugut AI. Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis 2008;23:559-68. [PMID: 18330581 DOI: 10.1007/s00384-008-0456-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 5.2] [Reference Citation Analysis]
278 Louie SG, Ely B, Lenz HJ, Albain KS, Gotay C, Coleman D, Raghavan D, Shields AF, Gold PJ, Blanke CD. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). Br J Cancer 2013;109:1744-9. [PMID: 24022189 DOI: 10.1038/bjc.2013.517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
279 Znojek P, Willmore E, Curtin NJ. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer 2014;111:1319-26. [PMID: 25003660 DOI: 10.1038/bjc.2014.378] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
280 Ma D, Tremblay P, Mahngar K, Akbari-Asl P, Collins J, Hudlicky T, McNulty J, Pandey S. A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen. Invest New Drugs 2012;30:1012-27. [PMID: 21494837 DOI: 10.1007/s10637-011-9668-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
281 Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. Front Oncol 2021;11:688709. [PMID: 34211856 DOI: 10.3389/fonc.2021.688709] [Reference Citation Analysis]
282 Allen WL, Jithesh PV, Oliver GR, Proutski I, Longley DB, Lenz HJ, Proutski V, Harkin P, Johnston PG. The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information. BMC Cancer 2010;10:687. [PMID: 21172019 DOI: 10.1186/1471-2407-10-687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
283 Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D 2011;11:101-11. [PMID: 21679003 DOI: 10.2165/11590440-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
284 Leslie A, Steele RJ. Management of colorectal cancer. Postgrad Med J 2002;78:473-8. [PMID: 12185221 DOI: 10.1136/pmj.78.922.473] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
285 Zhang K, Meng Y, Cao X, Xu Y, Du M, Wu Y, Liu L. Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer. Cancer Med 2019;8:3428-36. [PMID: 31090204 DOI: 10.1002/cam4.2215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
286 Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T, Sugihara K. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer. 2006;94:1130-1135. [PMID: 16570038 DOI: 10.1038/sj.bjc.6603072] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
287 Patel JN, O'Neil BH, Deal AM, Ibrahim JG, Sherrill GB, Olajide OA, Atluri PM, Inzerillo JJ, Chay CH, McLeod HL, Walko CM. A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist 2014;19:959-65. [PMID: 25117066 DOI: 10.1634/theoncologist.2014-0132] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
288 Cho YH, Ro EJ, Yoon JS, Mizutani T, Kang DW, Park JC, Il Kim T, Clevers H, Choi KY. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation. Nat Commun 2020;11:5321. [PMID: 33087710 DOI: 10.1038/s41467-020-19173-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
289 Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci 2015;106:1722-9. [PMID: 26426205 DOI: 10.1111/cas.12827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
290 Azoulay D, Andreani P, Maggi U, Salloum C, Perdigao F, Sebagh M, Lemoine A, Adam R, Castaing D. Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann Surg. 2006;244:80-88. [PMID: 16794392 DOI: 10.1097/01.sla.0000218092.83675.bc] [Cited by in Crossref: 113] [Cited by in F6Publishing: 75] [Article Influence: 7.5] [Reference Citation Analysis]
291 Zhan W, Li H, Guo Y, Du G, Wu Y, Zhang D. Construction of Biocompatible Dual-Drug Loaded Complicated Nanoparticles for in vivo Improvement of Synergistic Chemotherapy in Esophageal Cancer. Front Oncol 2020;10:622. [PMID: 32432038 DOI: 10.3389/fonc.2020.00622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
292 Wong CK, Lambert AW, Ozturk S, Papageorgis P, Lopez D, Shen N, Sen Z, Abdolmaleky HM, Győrffy B, Feng H, Thiagalingam S. Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. Mol Cancer Res 2020;18:414-23. [PMID: 31932471 DOI: 10.1158/1541-7786.MCR-19-0525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
293 Zhang L, Wang H, Li W, Zhong J, Yu R, Huang X, Wang H, Tan Z, Wang J, Zhang Y. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Oncotarget 2017;8:3289-303. [PMID: 27924057 DOI: 10.18632/oncotarget.13753] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
294 Nassour I, Polanco PM. Minimally Invasive Liver Surgery for Hepatic Colorectal Metastases. Curr Colorectal Cancer Rep 2016;12:103-12. [PMID: 27570500 DOI: 10.1007/s11888-016-0316-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
295 Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319:2486-2496. [PMID: 29946728 DOI: 10.1001/jama.2018.7855] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 21.3] [Reference Citation Analysis]
296 Valentí Moreno V, Brunet Vidal J, Manzano Alemany H, Salud Salvia A, Llobera Serentill M, Cabezas Montero I, Servitja Tormo S, Sopena Bert E, Gumà Padró J. Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients. Clin Transl Oncol 2006;8:208-12. [PMID: 16648121 DOI: 10.1007/s12094-006-0012-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
297 Schoemaker NE, Kuppens IE, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer. 2004;91:1434-1441. [PMID: 15381932 DOI: 10.1038/sj.bjc.6602172] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
298 Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924. [PMID: 11085200 DOI: 10.2165/00003495-200060040-00005] [Cited by in Crossref: 135] [Cited by in F6Publishing: 125] [Article Influence: 6.8] [Reference Citation Analysis]
299 Cheung FP, Alam NZ, Wright GM. The Past, Present and Future of Pulmonary Metastasectomy: A Review Article. Ann Thorac Cardiovasc Surg 2019;25:129-41. [PMID: 30971647 DOI: 10.5761/atcs.ra.18-00229] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
300 Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011;8:210-5. [PMID: 21448307 DOI: 10.7150/ijms.8.210] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
301 Legué LM, Bernards N, Lemmens VE, de Hingh IH, Creemers GJ, van Erning FN. Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice. United European Gastroenterol J 2019;7:1380-8. [PMID: 31839964 DOI: 10.1177/2050640619858211] [Reference Citation Analysis]
302 Herbrand AK, Schmitt AM, Briel M, Ewald H, Goldkuhle M, Diem S, Hoogkamer A, Joerger M, Moffa G, Novak U, Hemkens LG, Kasenda B. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw Open 2021;4:e210380. [PMID: 33651108 DOI: 10.1001/jamanetworkopen.2021.0380] [Reference Citation Analysis]
303 Wang Y, Wei Q, Chen Y, Long S, Yao Y, Fu K. Identification of Hub Genes Associated With Sensitivity of 5-Fluorouracil Based Chemotherapy for Colorectal Cancer by Integrated Bioinformatics Analysis. Front Oncol 2021;11:604315. [PMID: 33912443 DOI: 10.3389/fonc.2021.604315] [Reference Citation Analysis]
304 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
305 Feliu J, Salud A, Escudero P, López-Gómez L, Pericay C, Castañón C, de Tejada MR, Rodríguez-García JM, Martínez MP, Martín MS, Sánchez JJ, Barón MG; Oncopaz Cooperative Group and Associated Hospitals. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. Br J Cancer 2004;90:1502-7. [PMID: 15083176 DOI: 10.1038/sj.bjc.6601713] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
306 Guo JR, Chen QQ, Lam CW, Wang CY, Xu FG, Liu BM, Zhang W. Effect of Phyllanthus amarus Extract on 5-Fluorouracil-Induced Perturbations in Ribonucleotide and Deoxyribonucleotide Pools in HepG2 Cell Line. Molecules 2016;21:E1254. [PMID: 27657029 DOI: 10.3390/molecules21091254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
307 Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 2009;16:30. [PMID: 19272130 DOI: 10.1186/1423-0127-16-30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
308 Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis 2014;29:1031-42. [PMID: 24953060 DOI: 10.1007/s00384-014-1928-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
309 Meulenbeld HJ, Creemers GJ. First-line treatment strategies for elderly patients with metastatic colorectal cancer. Drugs Aging 2007;24:223-38. [PMID: 17362050 DOI: 10.2165/00002512-200724030-00004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
310 Kikuchi D, Saito M, Saito K, Watanabe Y, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated solute carrier family 37 member 1 in colorectal cancer is associated with poor patient outcome and metastasis. Oncol Lett 2018;15:2065-72. [PMID: 29434906 DOI: 10.3892/ol.2017.7559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
311 Amano R, Yamada N, Nakata B, Kimura K, Yashiro M, Ohira M, Hirakawa K. Prognostic indicator for the resection of liver metastasis of colorectal cancer. Surg Today 2014;44:1287-92. [PMID: 23979110 DOI: 10.1007/s00595-013-0699-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
312 Siri M, Behrouj H, Dastghaib S, Zamani M, Likus W, Rezaie S, Hudecki J, Khazayel S, Łos MJ, Mokarram P, Ghavami S. Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition. Arch Immunol Ther Exp (Warsz) 2021;69:26. [PMID: 34536148 DOI: 10.1007/s00005-021-00629-2] [Reference Citation Analysis]
313 Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:866-71. [PMID: 20038727 DOI: 10.1200/JCO.2009.23.6125] [Cited by in Crossref: 112] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
314 Mayrbäurl B, Giesinger JM, Burgstaller S, Piringer G, Holzner B, Thaler J. Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study. Support Care Cancer 2016;24:667-74. [PMID: 26123602 DOI: 10.1007/s00520-015-2828-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
315 Whitehouse PA, Mercer SJ, Knight LA, Di Nicolantonio F, O'Callaghan A, Cree IA; Portsmouth Upper GI and Colorectal Cancer Multidisciplinary Teams. Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C. Br J Cancer 2003;89:2299-304. [PMID: 14676810 DOI: 10.1038/sj.bjc.6601403] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
316 Blanas A, Zaal A, van der Haar Àvila I, Kempers M, Kruijssen L, de Kok M, Popovic MA, van der Horst JC, J van Vliet S. FUT9-Driven Programming of Colon Cancer Cells towards a Stem Cell-Like State. Cancers (Basel) 2020;12:E2580. [PMID: 32927726 DOI: 10.3390/cancers12092580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
317 Braun MS, Seymour MT. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol. 2011;3:43-52. [PMID: 21789155 DOI: 10.1177/1758834010388342] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
318 Leo S, Accettura C, Gnoni A, Licchetta A, Giampaglia M, Mauro A, Saracino V, Carr BI. Systemic treatment of gastrointestinal cancer in elderly patients. J Gastrointest Cancer. 2013;44:22-32. [PMID: 23150086 DOI: 10.1007/s12029-012-9447-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
319 Adam C, Pérez-López AM, Hamilton L, Rubio-Ruiz B, Bray TL, Sieger D, Brennan PM, Unciti-Broceta A. Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by Palladium-Functionalized Microdevices. Chemistry 2018;24:16783-90. [PMID: 30187973 DOI: 10.1002/chem.201803725] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
320 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, Ochi T, Okubo S, Futagawa S, Mashiko S, Nagaoka I. Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2012;4:621-4. [PMID: 23205073 DOI: 10.3892/ol.2012.823] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
321 Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 2010;14:375-84. [PMID: 21275455 DOI: 10.1007/BF03256395] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
322 Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ, Dotan E. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer 2016;122:3191-8. [PMID: 27379436 DOI: 10.1002/cncr.30077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
323 Okuno M, Goumard C, Mizuno T, Kopetz S, Omichi K, Tzeng CD, Chun YS, Lee JE, Vauthey JN, Conrad C. Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases. Br J Surg. 2018;105:1200-1209. [PMID: 29664996 DOI: 10.1002/bjs.10822] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
324 Nam SJ, Cho JY, Lee HS, Choe G, Jang JJ, Yoon YS, Han HS, Kim H. Chemotherapy-associated hepatopathy in korean colorectal cancer liver metastasis patients: oxaliplatin-based chemotherapy and sinusoidal injury. Korean J Pathol 2012;46:22-9. [PMID: 23109974 DOI: 10.4132/KoreanJPathol.2012.46.1.22] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
325 Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y. Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). Front Oncol 2021;11:576036. [PMID: 33763345 DOI: 10.3389/fonc.2021.576036] [Reference Citation Analysis]
326 Li J, Li J, Lyu N, Ma Y, Liu F, Feng Y, Yao L, Hou Z, Song X, Zhao H, Li X, Wang Y, Xiao C, Zhu B. Composition of fecal microbiota in low-set rectal cancer patients treated with FOLFOX. Ther Adv Chronic Dis 2020;11:2040622320904293. [PMID: 32153743 DOI: 10.1177/2040622320904293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
327 Landre T, Maillard E, Taleb C, Ghebriou D, Guetz GD, Zelek L, Aparicio T. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. Int J Colorectal Dis 2018;33:1125-30. [PMID: 29680896 DOI: 10.1007/s00384-018-3053-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
328 Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs 2008;10:177-92. [PMID: 18454570 DOI: 10.2165/00148581-200810030-00006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
329 Reinacher-Schick A. [Systemic treatment of advanced colorectal cancer]. Pathologe 2008;29 Suppl 2:191-5. [PMID: 18791719 DOI: 10.1007/s00292-008-1071-6] [Reference Citation Analysis]
330 Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009;27:2848-2854. [PMID: 19380443 DOI: 10.1200/jco.2008.20.4552] [Cited by in Crossref: 46] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
331 Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27:3379-84. [PMID: 19487380 DOI: 10.1200/JCO.2008.20.9817] [Cited by in Crossref: 260] [Cited by in F6Publishing: 100] [Article Influence: 21.7] [Reference Citation Analysis]
332 Galvano A, Incorvaia L, Badalamenti G, Rizzo S, Guarini A, Cusenza S, Castellana L, Barraco N, Calò V, Cutaia S, Currò G, Silvestris N, Beretta GD, Bazan V, Russo A. How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1189. [PMID: 31443300 DOI: 10.3390/cancers11081189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
333 Zhang B, Zhang B, Chen X, Bae S, Singh K, Washington MK, Datta PK. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br J Cancer. 2014;110:946-957. [PMID: 24384683 DOI: 10.1038/bjc.2013.789] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
334 He J, Pei L, Jiang H, Yang W, Chen J, Liang H. Chemoresistance of colorectal cancer to 5-fluorouracil is associated with silencing of the BNIP3 gene through aberrant methylation. J Cancer 2017;8:1187-96. [PMID: 28607593 DOI: 10.7150/jca.18171] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
335 Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res 2009;18:1095-103. [PMID: 19626462 DOI: 10.1007/s11136-009-9513-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
336 Kjeldsen E, Nielsen CJF, Roy A, Tesauro C, Jakobsen AK, Stougaard M, Knudsen BR. Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5. Cancer Genomics Proteomics 2018;15:91-114. [PMID: 29496689 DOI: 10.21873/cgp.20068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
337 de Gramont A, Tournigand C, Louvet C, Maindrault-Goebel F, André T. First-line therapy for advanced colorectal cancer. Curr Oncol Rep 2005;7:167-72. [PMID: 15847706 DOI: 10.1007/s11912-005-0069-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
338 Siesing C, Sorbye H, Dragomir A, Pfeiffer P, Qvortrup C, Pontén F, Jirström K, Glimelius B, Eberhard J. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS One 2017;12:e0182512. [PMID: 28800641 DOI: 10.1371/journal.pone.0182512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
339 Damianovich D, Adena M, Tebbutt NC. Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. Br J Cancer 2007;96:546-50. [PMID: 17285136 DOI: 10.1038/sj.bjc.6603590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
340 Yi BR, Park MA, Lee HR, Kang NH, Choi KJ, Kim SU, Choi KC. Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models. Mol Oncol 2013;7:543-54. [PMID: 23403306 DOI: 10.1016/j.molonc.2013.01.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
341 Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 2010;66:1113-21. [PMID: 20953860 DOI: 10.1007/s00280-010-1269-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
342 Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2010; 2(1): 19-30 [PMID: 21160813 DOI: 10.4251/wjgo.v2.i1.19] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
343 Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011;15:410-415. [PMID: 21253876 DOI: 10.1007/s11605-011-1423-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
344 Shamimi-Noori S, Gonsalves CF, Shaw CM. Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.Semin Intervent Radiol. 2017;34:145-166. [PMID: 28579683 DOI: 10.1055/s-0037-1602712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
345 Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastritis E, Rigatos SK, Xiros N, Petsas T, Economopoulos T, Sakadamis AK, Fountzilas G; Hellenic Cooperative Oncology Group. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer. 2005;35:103-109. [PMID: 15879624 DOI: 10.1385/ijgc:35:2:103] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
346 Beklen H, Gulfidan G, Arga KY, Mardinoglu A, Turanli B. Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer. Front Oncol. 2020;10:1273. [PMID: 32903699 DOI: 10.3389/fonc.2020.01273] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
347 Zulkifli A, Tan FH, Areeb Z, Stuart SF, Gomez J, Paradiso L, Luwor RB. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer. Int J Mol Sci 2021;22:7114. [PMID: 34281166 DOI: 10.3390/ijms22137114] [Reference Citation Analysis]
348 Lim SW, Lee S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. J Cancer 2018;9:2910-5. [PMID: 30123359 DOI: 10.7150/jca.24948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
349 Buhl IK, Gerster S, Delorenzi M, Jensen T, Jensen PB, Bosman F, Tejpar S, Roth A, Brunner N, Hansen A, Knudsen S. Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data. PLoS One 2016;11:e0155123. [PMID: 27171152 DOI: 10.1371/journal.pone.0155123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
350 Aoyama T, Kashiwabara K, Oba K, Honda M, Sadahiro S, Hamada C, Maeda H, Mayanagi S, Kanda M, Sakamoto J. Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials. Cancer Med. 2017;6:2523-2530. [PMID: 28948714 DOI: 10.1002/cam4.1208] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
351 Yeh YS, Tsai HL, Huang CW, Wang JH, Lin YW, Tang HC, Sung YC, Wu CC, Lu CY, Wang JY. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Trials 2016;17:46. [PMID: 26811156 DOI: 10.1186/s13063-016-1153-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
352 De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743 [PMID: 25110411 DOI: 10.3748/wjg.v20.i29.9732] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
353 Van der Speeten K, Stuart OA, Sugarbaker PH. Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol. 2009;6:72-81. [PMID: 19275544 DOI: 10.2174/157016309787581084] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
354 Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, Ro SG, Kim SY, Kim YS, Lee JS. Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 2009;24:209-18. [PMID: 18830613 DOI: 10.1007/s00384-008-0590-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
355 Eveno C, Karoui M, Gayat E, Luciani A, Auriault ML, Kluger MD, Baumgaertner I, Baranes L, Laurent A, Tayar C, Azoulay D, Cherqui D. Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections. HPB (Oxford) 2013;15:359-64. [PMID: 23458567 DOI: 10.1111/j.1477-2574.2012.00581.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
356 Zhou Y, Bollu LR, Tozzi F, Ye X, Bhattacharya R, Gao G, Dupre E, Xia L, Lu J, Fan F, Bellister S, Ellis LM, Weihua Z. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol Cancer Ther 2013;12:2782-91. [PMID: 24132143 DOI: 10.1158/1535-7163.MCT-13-0098] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
357 Tsoulfas G, Pramateftakis MG, Kanellos I. Surgical treatment of hepatic metastases from colorectal cancer. World J Gastrointest Oncol 2011; 3(1): 1-9 [PMID: 21267397 DOI: 10.4251/wjgo.v3.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
358 Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG)., Dutch Colorectal Cancer Group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19:390. [PMID: 31023318 DOI: 10.1186/s12885-019-5545-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
359 Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 2012;106:18-24. [PMID: 22108516 DOI: 10.1038/bjc.2011.498] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
360 Hirashima T, Nagai T, Shigeoka H, Tamura Y, Yoshida H, Kawahara K, Kondoh Y, Sakai K, Hashimoto S, Fujishima M, Shiroyama T, Tamiya M, Morishita N, Suzuki H, Okamoto N, Kawase I. Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study. BMC Cancer 2014;14:770. [PMID: 25326267 DOI: 10.1186/1471-2407-14-770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
361 Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J. 2013;Epub ahead of print. [PMID: 23529007 DOI: 10.1038/tpj.2013.10] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 9.4] [Reference Citation Analysis]
362 Emi T, Michaud K, Orton E, Santilli G, Linh C, O'Connell M, Issa F, Kennedy S. Ultrasonic Generation of Pulsatile and Sequential Therapeutic Delivery Profiles from Calcium-Crosslinked Alginate Hydrogels. Molecules 2019;24:E1048. [PMID: 30884862 DOI: 10.3390/molecules24061048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
363 Goff LW, Benson AB 3rd, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Invest New Drugs 2012;30:290-8. [PMID: 20857171 DOI: 10.1007/s10637-010-9528-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
364 Roy A, Tesauro C, Frøhlich R, Hede MS, Nielsen MJ, Kjeldsen E, Bonven B, Stougaard M, Gromova I, Knudsen BR. Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I. PLoS One 2014;9:e99628. [PMID: 24960044 DOI: 10.1371/journal.pone.0099628] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
365 Muggia FM, Peters GJ, Landolph JR Jr. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009;8:992-9. [PMID: 19417150 DOI: 10.1158/1535-7163.MCT-08-0731] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
366 Tanaka K, Shimada H, Matsumoto C, Matsuo K, Takeda K, Nagano Y, Togo S. Impact of the degree of liver resection on survival for patients with multiple liver metastases from colorectal cancer. World J Surg. 2008;32:2057-2069. [PMID: 18454272 DOI: 10.1007/s00268-008-9610-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
367 Fadlullah MZ, Chiang IK, Dionne KR, Yee PS, Gan CP, Sam KK, Tiong KH, Ng AK, Martin D, Lim KP, Kallarakkal TG, Mustafa WM, Lau SH, Abraham MT, Zain RB, Rahman ZA, Molinolo A, Patel V, Gutkind JS, Tan AC, Cheong SC. Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. Oncotarget 2016;7:27802-18. [PMID: 27050151 DOI: 10.18632/oncotarget.8533] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
368 Tapia Rico G, Klevansky M, Townsend A, Price T. Synovial metastasis of the knee in a KRAS mutant rectal adenocarcinoma patient. BMJ Case Rep 2017;2017:bcr-2017-220008. [PMID: 28784880 DOI: 10.1136/bcr-2017-220008] [Reference Citation Analysis]
369 McCulloch M, Broffman M, van der Laan M, Hubbard A, Kushi L, Abrams DI, Gao J, Colford JM Jr. Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther 2011;10:240-59. [PMID: 21964510 DOI: 10.1177/1534735411406539] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
370 Klautke G, Küchenmeister U, Foitzik T, Ludwig K, Prall F, Klar E, Fietkau R. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer. 2006;94:976-981. [PMID: 16552435 DOI: 10.1038/sj.bjc.6603053] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
371 Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017;317:2392-2401. [PMID: 28632865 DOI: 10.1001/jama.2017.7105] [Cited by in Crossref: 334] [Cited by in F6Publishing: 325] [Article Influence: 83.5] [Reference Citation Analysis]
372 Won YW, Lim YH, Park HY, Oh HS, Choi JH, Lee YY, Kim IS, Choi IY, Ahn MJ. Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapy. Cancer Res Treat 2004;36:235-9. [PMID: 20368840 DOI: 10.4143/crt.2004.36.4.235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
373 Luput L, Sesarman A, Porfire A, Achim M, Muntean D, Casian T, Patras L, Rauca VF, Drotar DM, Stejerean I, Tomuta I, Vlase L, Dragos N, Toma VA, Licarete E, Banciu M. Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. Cancer Sci 2020;111:1344-56. [PMID: 31960547 DOI: 10.1111/cas.14312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
374 Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer 2001;84:579-85. [PMID: 11207057 DOI: 10.1054/bjoc.2000.1600] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
375 Yoshino T, Oki E, Nozawa H, Eguchi-Nakajima T, Taniguchi H, Morita S, Takenaka N, Ozawa D, Shirao K. Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. ESMO Open 2018;3:e000411. [PMID: 30167332 DOI: 10.1136/esmoopen-2018-000411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
376 Wang CZ, Li B, Wen XD, Zhang Z, Yu C, Calway TD, He TC, Du W, Yuan CS. Paraptosis and NF-κB activation are associated with protopanaxadiol-induced cancer chemoprevention. BMC Complement Altern Med 2013;13:2. [PMID: 23281928 DOI: 10.1186/1472-6882-13-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
377 Wood JP, Smith AJ, Bowman KJ, Thomas AL, Jones GD. Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo. Cancer Med 2015;4:1309-21. [PMID: 26108357 DOI: 10.1002/cam4.477] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
378 Pan DC, Krishnan V, Salinas AK, Kim J, Sun T, Ravid S, Peng K, Wu D, Nurunnabi M, Nelson JA, Niziolek Z, Guo J, Mitragotri S. Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioeng Transl Med 2021;6:e10166. [PMID: 33532580 DOI: 10.1002/btm2.10166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 Reita D, Bour C, Benbrika R, Groh A, Pencreach E, Guérin E, Guenot D. Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. Cancers (Basel) 2019;11:E1581. [PMID: 31627299 DOI: 10.3390/cancers11101581] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
380 Sun L, Huang Y, Liu Y, Zhao Y, He X, Zhang L, Wang F, Zhang Y. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell Death Dis 2018;9:911. [PMID: 30185800 DOI: 10.1038/s41419-018-0943-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
381 Toden S, Kunitoshi S, Cardenas J, Gu J, Hutchins E, Van Keuren-Jensen K, Uetake H, Toiyama Y, Goel A. Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer. JCI Insight 2019;4:125294. [PMID: 30895943 DOI: 10.1172/jci.insight.125294] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
382 Hebbar M, Ychou M, Ducreux M. Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2009;135:749-52. [PMID: 19343364 DOI: 10.1007/s00432-009-0580-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
383 崔恒官, 曹秀峰. 手术为主的大肠癌综合治疗. 世界华人消化杂志 2008; 16(16): 1774-1780 [DOI: 10.11569/wcjd.v16.i16.1774] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
384 Cheng YM, Lin PL, Wu DW, Wang L, Huang CC, Lee H. PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2. Oncotarget 2018;9:26342-52. [PMID: 29899863 DOI: 10.18632/oncotarget.25254] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
385 Tsunedomi R, Hazama S, Okayama N, Oka M, Nagano H. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray. Cancer Sci 2017;108:1504-9. [PMID: 28474802 DOI: 10.1111/cas.13272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
386 Guo J, Chen Q, Lam CW, Wang C, Wong VK, Xu F, Jiang Z, Zhang W. Application of artificial neural network to investigate the effects of 5-fluorouracil on ribonucleotides and deoxyribonucleotides in HepG2 cells. Sci Rep 2015;5:16861. [PMID: 26578061 DOI: 10.1038/srep16861] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
387 Midgley RS, Yanagisawa Y, Kerr DJ. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 2009;6:108-20. [PMID: 19153564 DOI: 10.1038/ncpgasthep1337] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
388 Nietzer S, Baur F, Sieber S, Hansmann J, Schwarz T, Stoffer C, Häfner H, Gasser M, Waaga-Gasser AM, Walles H, Dandekar G. Mimicking Metastases Including Tumor Stroma: A New Technique to Generate a Three-Dimensional Colorectal Cancer Model Based on a Biological Decellularized Intestinal Scaffold. Tissue Eng Part C Methods 2016;22:621-35. [PMID: 27137941 DOI: 10.1089/ten.TEC.2015.0557] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
389 Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20(30): 10316-10330 [PMID: 25132748 DOI: 10.3748/wjg.v20.i30.10316] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
390 Wang H, Huang L, Gao P, Zhu Z, Ye W, Ding H, Fang L. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. BMJ Open 2020;10:e030738. [PMID: 32051297 DOI: 10.1136/bmjopen-2019-030738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Saxena A, Chua TC, Chu FC, Ng KM, Herle P, Morris DL. Impact of treatment modality and number of lesions on recurrence and survival outcomes after treatment of colorectal cancer liver metastases. J Gastrointest Oncol 2014;5:46-56. [PMID: 24490042 DOI: 10.3978/j.issn.2078-6891.2013.055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
392 Tie Y, Chen C, Yang Y, Qian Z, Yuan H, Wang H, Tang H, Peng Y, Du X, Liu B. Upregulation of let-7f-5p promotes chemotherapeutic resistance in colorectal cancer by directly repressing several pro-apoptotic proteins. Oncol Lett 2018;15:8695-702. [PMID: 29805607 DOI: 10.3892/ol.2018.8410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
393 Jourabchi N, Sauk S, Hoffman C, Lee EW, Kee ST. Intercostal artery pseudoaneurysm formation after irinotecan transarterial chemoembolization of a spinal metastasis from colorectal cancer. Case Rep Radiol 2012;2012:146540. [PMID: 23316405 DOI: 10.1155/2012/146540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
394 Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Grémy G, Couillault C, Lajémi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S. Deciphering cellular states of innate tumor drug responses. Genome Biol 2006;7:R19. [PMID: 16542501 DOI: 10.1186/gb-2006-7-3-r19] [Cited by in F6Publishing: 82] [Reference Citation Analysis]
395 Sheikh HY, Valle JW, Palmer K, Sjursen A, Craven O, Wilson G, Swindell R, Saunders MP. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. Br J Cancer 2007;96:38-43. [PMID: 17213824 DOI: 10.1038/sj.bjc.6603521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
396 Samawi HH, Brezden-Masley C, Afzal AR, Cheung WY, Dolley A. Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada. Curr Oncol 2019;26:319-29. [PMID: 31708650 DOI: 10.3747/co.26.5107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
397 Arru M, Aldrighetti L, Castoldi R, Di Palo S, Orsenigo E, Stella M, Pulitanò C, Gavazzi F, Ferla G, Di Carlo V, Staudacher C. Analysis of Prognostic Factors Influencing Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer. World J Surg 2008;32:93-103. [DOI: 10.1007/s00268-007-9285-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
398 Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol 2011;179:3032-44. [PMID: 21978492 DOI: 10.1016/j.ajpath.2011.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
399 Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30:608-615. [PMID: 22253466 DOI: 10.1200/jco.2011.38.9650] [Cited by in Crossref: 93] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
400 Frank D, Jumonville A, Loconte NK, Schelman WR, Mulkerin D, Lubner S, Richter K, Winterle N, Wims MB, Dietrich L, Winkler JM, Volk M, Kim K, Holen KD. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. J Gastrointest Oncol 2012;3:90-6. [PMID: 22811876 DOI: 10.3978/j.issn.2078-6891.2011.049] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
401 Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296-1310. [PMID: 18471507 DOI: 10.1053/j.gastro.2008.02.098] [Cited by in Crossref: 307] [Cited by in F6Publishing: 271] [Article Influence: 23.6] [Reference Citation Analysis]
402 Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer 2016;6:21-30. [PMID: 28190957 DOI: 10.2147/GICTT.S97740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
403 Goel S, Desai K, Karri S, Gollamudi R, Chaudhary I, Bulgaru A, Kaubisch A, Goldberg G, Einstein M, Camacho F, Baker S, Mani S. Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Invest New Drugs 2007;25:237-45. [PMID: 17195945 DOI: 10.1007/s10637-006-9028-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
404 Zafar SY, Marcello JE, Wheeler JL, Rowe KL, Morse MA, Herndon JE, Abernethy AP. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 2009;5:228-33. [PMID: 20856733 DOI: 10.1200/JOP.091010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
405 Gavriilidis P, Tobias A, Sutcliffe RP, Azoulay D, Roberts KJ. Network Meta-Analysis of Adjuvant Chemotherapy following Resection of Colorectal Liver Metastases. Gastrointest Tumors 2018;5:21-31. [PMID: 30574478 DOI: 10.1159/000490763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
406 Demols A, Van Laethem JL. Adjuvant chemotherapy for colorectal cancer. Curr Gastroenterol Rep. 2002;4:420-426. [PMID: 12228045 DOI: 10.1007/s11894-002-0013-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
407 Toden S, Tran HM, Tovar-Camargo OA, Okugawa Y, Goel A. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016;7:16158-16171. [PMID: 26930714 DOI: 10.18632/oncotarget.7567] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 19.5] [Reference Citation Analysis]
408 Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Target Oncol 2016;11:293-308. [PMID: 26687849 DOI: 10.1007/s11523-015-0400-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
409 Li AJ, Li HG, Tang EJ, Wu W, Chen Y, Jiang HH, Lin MB, Yin L. PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients. World J Gastroenterol 2018; 24(5): 631-640 [PMID: 29434452 DOI: 10.3748/wjg.v24.i5.631] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
410 Wang D, Zhang X, Zhang Y, Wu Y, Guan X, Zhu W, Wang M, Qi C, Shen B. Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer. Onco Targets Ther 2018;11:8083-8. [PMID: 30519050 DOI: 10.2147/OTT.S180145] [Reference Citation Analysis]
411 Kajizono M, Saito M, Maeda M, Yamaji K, Fujiwara S, Kawasaki Y, Matsunaga H, Sendo T. Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer. Int J Clin Oncol 2013;18:684-8. [PMID: 22678464 DOI: 10.1007/s10147-012-0427-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
412 Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009;6:207-218. [PMID: 19333227 DOI: 10.1038/nrclinonc.2009.16] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
413 Munireddy S, Katz S, Somasundar P, Espat NJ. Thermal tumor ablation therapy for colorectal cancer hepatic metastasis. J Gastrointest Oncol 2012;3:69-77. [PMID: 22811871 DOI: 10.3978/j.issn.2078-6891.2012.008] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
414 Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, Mishima H, Maeda K, Sakamoto J, Koda K. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. Invest New Drugs. 2013;31:1321-1329. [PMID: 23817973 DOI: 10.1007/s10637-013-9982-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
415 Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World J Gastroenterol 2014; 20(24): 7602-7621 [PMID: 24976699 DOI: 10.3748/wjg.v20.i24.7602] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
416 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409ott-7-1817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
417 Ren Y, Zhao C, He Y, Xu H, Min X. Long non-coding RNA bladder cancer-associated transcript 2 contributes to disease progression, chemoresistance and poor survival of patients with colorectal cancer. Oncol Lett 2019;18:2050-8. [PMID: 31423277 DOI: 10.3892/ol.2019.10487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
418 de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;. [PMID: 29520731 DOI: 10.1007/s40262-018-0644-7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 45.0] [Reference Citation Analysis]
419 Li Y, Guo D, Zhang Y, Wang L, Sun T, Li Z, Zhang X, Wang S, Chen Y, Wu A. Rapid screening for individualized chemotherapy optimization of colorectal cancer: A novel conditional reprogramming technology-based functional diagnostic assay. Transl Oncol 2021;14:100935. [PMID: 33190042 DOI: 10.1016/j.tranon.2020.100935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
420 Feliu J, Vicent JM, García-Girón C, Constela M, Fonseca E, Aparicio J, Lomas M, Antón-Aparicio L, Dorta FJ, Gonzalez-Baron M; Oncopaz Cooperative Group and Associated Hospitals. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer 2004;91:1758-62. [PMID: 15505621 DOI: 10.1038/sj.bjc.6602217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
421 Stathopoulos GP, Dimitroulis J, Antoniou D, Katis C, Tsavdaridis D, Armenaki O, Marosis C, Michalopoulou P, Grigoratou T, Stathopoulos J. Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial. Br J Cancer 2005;93:1106-11. [PMID: 16251879 DOI: 10.1038/sj.bjc.6602827] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
422 Qi H, Fan W. Value of ablation therapy in the treatment of lung metastases. Thorac Cancer 2018;9:199-207. [PMID: 29193688 DOI: 10.1111/1759-7714.12567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
423 Ab Mutalib NS, Md Yusof NF, Abdul SN, Jamal R. Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update. Front Pharmacol 2017;8:736. [PMID: 29075194 DOI: 10.3389/fphar.2017.00736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
424 Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15(4): 449-456 [PMID: 19152449 DOI: 10.3748/wjg.15.449] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
425 Kim JH, Zang DY, Chung IJ, Cho SH, Park KU, Oh HS, Lee KH, Lee BH, Kim MJ, Park CK, Han B, Kim HS, Choi DR, Song HH, Jung JY. A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer. J Cancer. 2015;6:1041-1048. [PMID: 26366218 DOI: 10.7150/jca.12819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
426 Tebbutt NC, Norman AR, Cunningham D, Allen M, Chau I, Oates J, Hill M. Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. Br J Cancer 2003;88:1510-5. [PMID: 12771914 DOI: 10.1038/sj.bjc.6600917] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
427 Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1-7. [PMID: 16371728 DOI: 10.1097/01.sla.0000193603.26265.c3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
428 Kurkjian C, Kummar S. Advances in the treatment of metastatic colorectal cancer. Am J Ther 2009;16:412-20. [PMID: 19955859 DOI: 10.1097/MJT.0b013e3181907ed9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
429 Ogata Y, Tokunaga S, Emi Y, Oki E, Saeki H, Shirabe K, Hasegawa H, Sadanaga N, Samura H, Fujita F, Tanaka T, Kitazono M, Yamamoto M, Morikita T, Inomata M, Kakeji Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. Surg Today 2011;41:84-90. [PMID: 21191696 DOI: 10.1007/s00595-010-4418-6] [Reference Citation Analysis]
430 Barone C, Landriscina M, Quirino M, Basso M, Pozzo C, Schinzari G, Di Leonardo G, D'Argento E, Trigila N, Cassano A. Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. Br J Cancer 2007;96:21-8. [PMID: 17164761 DOI: 10.1038/sj.bjc.6603496] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
431 Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol. 2007;25:773-780. [PMID: 17327601 DOI: 10.1200/jco.2006.07.4187] [Cited by in Crossref: 128] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
432 Mhaidat NM, Bouklihacene M, Thorne RF. 5-Fluorouracil-induced apoptosis in colorectal cancer cells is caspase-9-dependent and mediated by activation of protein kinase C-δ. Oncol Lett 2014;8:699-704. [PMID: 25013487 DOI: 10.3892/ol.2014.2211] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
433 Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall’Olio FG, Barbera MA, Pantaleo MA, Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol 2016; 22(2): 519-533 [PMID: 26811604 DOI: 10.3748/wjg.v22.i2.519] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
434 Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford). 2010;12:227-238. [PMID: 20590892 DOI: 10.1111/j.1477-2574.2010.00158.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
435 Silva VR, Corrêa RS, Santos LS, Soares MBP, Batista AA, Bezerra DP. A ruthenium-based 5-fluorouracil complex with enhanced cytotoxicity and apoptosis induction action in HCT116 cells. Sci Rep 2018;8:288. [PMID: 29321581 DOI: 10.1038/s41598-017-18639-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
436 Marques AM, Turner A, de Mello RA. Personalizing medicine for metastatic colorectal cancer: Current developments. World J Gastroenterol 2014; 20(30): 10425-10431 [PMID: 25132758 DOI: 10.3748/wjg.v20.i30.10425] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
437 Tanoue Y, Tanaka N, Nomura Y. Primary site resection is superior for incurable metastatic colorectal cancer. World J Gastroenterol 2010; 16(28): 3561-3566 [PMID: 20653065 DOI: 10.3748/wjg.v16.i28.3561] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
438 Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-Montefiore D. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer 2007;96:551-8. [PMID: 17262086 DOI: 10.1038/sj.bjc.6603570] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
439 Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006;94:964-8. [PMID: 16552436 DOI: 10.1038/sj.bjc.6603049] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
440 Feliu J, Castañón C, Salud A, Mel JR, Escudero P, Pelegrín A, López-Gómez L, Ruiz M, González E, Juárez F, Lizón J, Castro J, González-Barón M; Oncopaz Cooperative Group, Spain. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer 2005;93:1230-5. [PMID: 16265344 DOI: 10.1038/sj.bjc.6602860] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
441 Ishida K, Uesugi N, Hasegawa Y, Sugimoto R, Takahara T, Otsuka K, Nitta H, Kawasaki T, Wakabayashi G, Sugai T. Proposal for novel histological findings of colorectal liver metastases with preoperative chemotherapy. Pathol Int 2015;65:367-73. [PMID: 25940915 DOI: 10.1111/pin.12300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
442 Yoshidome H, Kimura F, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Mitsuhashi N, Takeuchi D, Iida A, Miyazaki M. Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? J Gastrointest Surg. 2008;12:1391-1398. [PMID: 18491195 DOI: 10.1007/s11605-008-0540-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
443 Burge ME, Smith D, Topham C, Jackson DP, Anthoney DA, Halstead F, Seymour MT. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer 2006;94:1281-6. [PMID: 16622464 DOI: 10.1038/sj.bjc.6603084] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
444 Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, Wilson RH, Jasani B, Taylor GR, Williams GT. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? Br J Cancer. 2014;110:2178-2186. [PMID: 24743706 DOI: 10.1038/bjc.2014.182] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
445 Yan TD, Stuart OA, Yoo D, Sugarbaker PH. Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med 2006;4:17. [PMID: 16606461 DOI: 10.1186/1479-5876-4-17] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
446 Xu Y, Qi J, Yang X, Wu E, Qian SY. Free radical derivatives formed from cyclooxygenase-catalyzed dihomo-γ-linolenic acid peroxidation can attenuate colon cancer cell growth and enhance 5-fluorouracil's cytotoxicity. Redox Biol 2014;2:610-8. [PMID: 25114837 DOI: 10.1016/j.redox.2014.01.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
447 Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010;7:318-325. [PMID: 20440283 DOI: 10.1038/nrclinonc.2010.62] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
448 Fujita KI, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015; 21(43): 12234-12248 [PMID: 26604633 DOI: 10.3748/wjg.v21.i43.12234] [Cited by in CrossRef: 121] [Cited by in F6Publishing: 106] [Article Influence: 20.2] [Reference Citation Analysis]
449 Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 2014;74:1125-37. [PMID: 25228368 DOI: 10.1007/s00280-014-2577-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
450 Alliot C. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 2004;91:599-600; author reply 599-601. [PMID: 15238988 DOI: 10.1038/sj.bjc.6602016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
451 Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T, Toh Y, Hyodo I, Nishina T, Furuhata T. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2010;21:766-771. [PMID: 19828562 DOI: 10.1093/annonc/mdp371] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
452 Lim HJ, Gill S, Speers C, Melosky B, Barnett J, Fitzgerald C, O'Reilly S, Kennecke H. Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study. J Oncol Pract 2009;5:153-8. [PMID: 20856627 DOI: 10.1200/JOP.0942001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
453 Vié N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer. 2008;7:14. [PMID: 18221502 DOI: 10.1186/1476-4598-7-14] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 6.8] [Reference Citation Analysis]
454 Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am. 2017;26:667-687. [PMID: 28923224 DOI: 10.1016/j.soc.2017.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
455 Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics 2009;10:1139-46. [PMID: 19604089 DOI: 10.2217/pgs.09.35] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
456 Sharma P, Shimura T, Banwait JK, Goel A. Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer. Carcinogenesis 2020;41:1385-94. [PMID: 32835374 DOI: 10.1093/carcin/bgaa090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
457 Vargas GM, Sheffield KM, Parmar AD, Han Y, Gajjar A, Brown KM, Riall TS. Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg 2014;18:369-77. [PMID: 24234244 DOI: 10.1007/s11605-013-2406-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
458 Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, Watson AJ, Margison GP, Midgley R, Middleton MR. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer. 2008;98:1614-1618. [PMID: 18475294 DOI: 10.1038/sj.bjc.6604366] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
459 Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Chen XX, Wang F, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol 2011; 17(43): 4779-4786 [PMID: 22147978 DOI: 10.3748/wjg.v17.i43.4779] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
460 Lee S 2nd, Park SH, Lim DH, Park KW, Lee J, Park JO, Park YS, Lim HY, Kang WK. A retrospective study of first-line combination chemotherapy in advanced colorectal cancer: a Korean single-center experience. Cancer Res Treat 2011;43:96-101. [PMID: 21811425 DOI: 10.4143/crt.2011.43.2.96] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
461 Brown KS. Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. Semin Intervent Radiol 2006;23:99-108. [PMID: 21326724 DOI: 10.1055/s-2006-939845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
462 LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2009;2:67. [PMID: 19948057 DOI: 10.1186/1755-8794-2-67] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.4] [Reference Citation Analysis]
463 Semrad TJ, Kim EJ. Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. J Gastrointest Oncol. 2016;7:S11-S20. [PMID: 27034809 DOI: 10.3978/j.issn.2078-6891.2015.094] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
464 Takakura Y, Ikeda S, Yoshimitsu M, Hinoi T, Sumitani D, Takeda H, Kawaguchi Y, Shimomura M, Tokunaga M, Okajima M, Ohdan H. Retroperitoneal abscess complicated with necrotizing fasciitis of the thigh in a patient with sigmoid colon cancer. World J Surg Oncol 2009;7:74. [PMID: 19811627 DOI: 10.1186/1477-7819-7-74] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
465 Chung FH, Chiang YR, Tseng AL, Sung YC, Lu J, Huang MC, Ma N, Lee HC. Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma. PLoS One. 2014;9:e86299. [PMID: 24475102 DOI: 10.1371/journal.pone.0086299] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
466 Santini D, Vincenzi B, Schiavon G, La Cesa A, Gasparro S, Vincenzi A, Tonini G. Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. BMC Cancer 2006;6:42. [PMID: 16504126 DOI: 10.1186/1471-2407-6-42] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
467 Watanabe Y, Saito M, Saito K, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncol Lett 2018;15:2756-62. [PMID: 29435001 DOI: 10.3892/ol.2017.7650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
468 Wang S, Wang L, Zhou Z, Deng Q, Li L, Zhang M, Liu L, Li Y. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. Sci Rep 2017;7:682. [PMID: 28386133 DOI: 10.1038/s41598-017-00839-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
469 Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol 2015;7:252-62. [PMID: 26327923 DOI: 10.1177/1758834015591952] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 7.7] [Reference Citation Analysis]
470 Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008;68:299-317. [PMID: 18257608 DOI: 10.2165/00003495-200868030-00004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
471 Granda TG, D'Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, Bissery MC, Lévi F. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002;86:999-1005. [PMID: 11953836 DOI: 10.1038/sj.bjc.6600168] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
472 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
473 Hernando-Cubero J, Matos-García I, Alonso-Orduña V, Capdevila J. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. J Gastrointest Cancer 2017;48:135-47. [PMID: 28397102 DOI: 10.1007/s12029-017-9946-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
474 Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer. 2010;103:581-589. [PMID: 20628391 DOI: 10.1038/sj.bjc.6605776] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 5.4] [Reference Citation Analysis]
475 Inoue Y, Miki C, Watanabe H, Hiro J, Toiyama Y, Ojima E, Yanagi H, Kusunoki M. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line. J Gastroenterol 2006;41:1149-57. [PMID: 17287894 DOI: 10.1007/s00535-006-1904-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
476 Yuan M, Wang Z, Zhao Y, Feng T, Lv W, Zhong H. Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital. Front Pharmacol 2021;12:632076. [PMID: 34122063 DOI: 10.3389/fphar.2021.632076] [Reference Citation Analysis]
477 Botrel TEA, Clark LGO, Paladini L, Clark OAC. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16:677. [PMID: 27558497 DOI: 10.1186/s12885-016-2734-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
478 Bélanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol Biol 2010;11:9. [PMID: 20096102 DOI: 10.1186/1471-2199-11-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
479 Parikh A. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. Journal of Gastrointestinal Surgery 2003;7:1082-8. [DOI: 10.1016/j.gassur.2003.08.005] [Cited by in Crossref: 153] [Cited by in F6Publishing: 136] [Article Influence: 8.5] [Reference Citation Analysis]
480 Losa F, Barrios P, Salazar R, Torres-melero J, Benavides M, Massuti T, Ramos I, Aranda E. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Oncol 2014;16:128-40. [DOI: 10.1007/s12094-013-1053-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
481 Santini D, Massacesi C, D'Angelillo RM, Marcucci F, Campisi C, Vincenzi B, Pilone A, Bianco V, Bonsignori M, Tonini G. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. Med Oncol. 2004;21:59-66. [PMID: 15034215 DOI: 10.1385/MO:21:1:59] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
482 Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015;6:185-200. [PMID: 25830038 DOI: 10.3978/j.issn.2078-6891.2014.112] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
483 刘莺, 梁冰, 刘文静, 王居峰, 樊青霞. 伊立替康联合奈达铂二线治疗晚期食管鳞癌24例. 世界华人消化杂志 2010; 18(3): 298-302 [DOI: 10.11569/wcjd.v18.i3.298] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
484 Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer. 2009;9:112. [PMID: 19366444 DOI: 10.1186/1471-2407-9-112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
485 De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, D' Andrea M, Buonadonna A, Zagonel V, Cecchin E, Innocenti F, Toffoli G. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One 2014;9:e84940. [PMID: 24497922 DOI: 10.1371/journal.pone.0084940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
486 Anselmino LE, Baglioni MV, Malizia F, Laluce NC, Etichetti CB, Marignac VLM, Rozados V, Scharovsky OG, Girardini J, Rico MJ, Menacho Márquez M. Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment. Sci Rep 2021;11:8091. [PMID: 33854147 DOI: 10.1038/s41598-021-87525-z] [Reference Citation Analysis]
487 Song X, Zhao Z, Barber B, Gregory C, Schutt D, Gao S. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract 2011;7:25s-30s. [PMID: 21886516 DOI: 10.1200/JOP.2011.000304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
488 Bacchetti S, Pasqual E, Crozzolo E, Pellarin A, Cagol PP. Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: a review of medical devices complications in 3172 patients. Med Devices (Auckl) 2009;2:31-40. [PMID: 22915912 DOI: 10.2147/mder.s4036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
489 Dimitroulis D, Nikiteas N, Troupis T, Patsouras D, Skandalakis P, Kouraklis G. Role of surgery in colorectal liver metastases: Too early or too late? World J Gastroenterol 2010; 16(28): 3484-3490 [PMID: 20653056 DOI: 10.3748/wjg.v16.i28.3484] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
490 Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemother Pharmacol 2017;80:599-608. [PMID: 28744667 DOI: 10.1007/s00280-017-3380-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
491 Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1-7. [PMID: 16371728 DOI: 10.1097/01.sla.0000193603.26265.c3] [Cited by in Crossref: 518] [Cited by in F6Publishing: 417] [Article Influence: 34.5] [Reference Citation Analysis]
492 Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H. Is there diversity among UGT1A1 polymorphism in Japan. World J Gastrointest Oncol 2012; 4(7): 170-175 [PMID: 22848786 DOI: 10.4251/wjgo.v4.i7.170] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
493 Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91. [PMID: 17537235 DOI: 10.1186/1471-2407-7-91] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
494 Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11:97-119. [PMID: 28085225 DOI: 10.1002/1878-0261.12018] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 17.5] [Reference Citation Analysis]
495 Cai X, Cao W, Ding H, Liu T, Zhou X, Wang M, Zhong M, Zhao Z, Xu Q, Wang L. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. J Cancer Res Clin Oncol. 2013;139:1579-1589. [PMID: 23892411 DOI: 10.1007/s00432-013-1480-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
496 Petrioli R, Sabatino M, Fiaschi AI, Marsili S, Pozzessere D, Messinese S, Correale P, Civitelli S, Tanzini G, Tani F, De Martino A, Marzocca G, Lorenzi M, Giorgi G, Francini G. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 2004;90:306-9. [PMID: 14735168 DOI: 10.1038/sj.bjc.6601521] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
497 Kassahun WT. Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis. World J Surg Oncol 2015;13:61. [PMID: 25890279 DOI: 10.1186/s12957-014-0420-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
498 Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190-1197. [PMID: 15026800 DOI: 10.1038/sj.bjc.6601676] [Cited by in Crossref: 275] [Cited by in F6Publishing: 234] [Article Influence: 16.2] [Reference Citation Analysis]
499 Kwon HC, Kim KT, Lee SA, Park JS, Kim SH, Kim JS, Kim HJ. Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer. Cancer Res Treat 2004;36:115-20. [PMID: 20396550 DOI: 10.4143/crt.2004.36.2.115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
500 Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH, Panasci L, Lorimer IA, Batist G. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs. 2005;23:165-170. [PMID: 15744593 DOI: 10.1007/s10637-005-5862-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
501 Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H, Muguruma K, Hirakawa K. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol 2015; 21(34): 9966-9973 [PMID: 26379401 DOI: 10.3748/wjg.v21.i34.9966] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
502 Linton SS, Sherwood SG, Drews KC, Kester M. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016;8:208-22. [PMID: 26153136 DOI: 10.1002/wnan.1358] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
503 Kollmannsberger C, Rick O, Klaproth H, Kubin T, Sayer HG, Hentrich M, Welslau M, Mayer F, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer 2002;87:729-32. [PMID: 12232755 DOI: 10.1038/sj.bjc.66000524] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
504 Stec R, Bodnar L, Szczylik C. Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. J Cancer Res Clin Oncol 2010;136:283-92. [PMID: 19693536 DOI: 10.1007/s00432-009-0660-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
505 Méndez M, Alfonso PG, Pujol E, González E, Castañon C, Cerezuela P, López-Mateos Y, Cruz JJ. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. Invest New Drugs 2005;23:243-51. [PMID: 15868381 DOI: 10.1007/s10637-005-6733-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
506 Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW. Guidelines for resection of colorectal cancer liver metastases. Gut. 2006;55 Suppl 3:iii1-iii8. [PMID: 16835351 DOI: 10.1136/gut.2006.098053] [Cited by in Crossref: 131] [Cited by in F6Publishing: 168] [Article Influence: 8.7] [Reference Citation Analysis]
507 Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031-1039. [PMID: 24590654 DOI: 10.1200/jco.2013.51.1857] [Cited by in Crossref: 145] [Cited by in F6Publishing: 72] [Article Influence: 20.7] [Reference Citation Analysis]
508 Burotto M, Hartley ML, Marshall JL, Pishvaian MJ. Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer 2012;1. [PMID: 24273599 DOI: 10.2217/crc.12.52] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
509 Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749-1759. [PMID: 21570111 DOI: 10.1016/s0140-6736(11)60399-1] [Cited by in Crossref: 250] [Cited by in F6Publishing: 103] [Article Influence: 25.0] [Reference Citation Analysis]
510 Solanki AA, Weichselbaum RR, Appelbaum D, Farrey K, Yenice KM, Chmura SJ, Salama JK. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol 2012;7:216. [PMID: 23244066 DOI: 10.1186/1748-717X-7-216] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
511 Giordano G, Febbraro A, Venditti M, Campidoglio S, Olivieri N, Raieta K, Parcesepe P, Imbriani GC, Remo A, Pancione M. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract. 2014;2014:526178. [PMID: 25136356 DOI: 10.1155/2014/526178] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
512 Blandizzi C, De Paolis B, Colucci R, Lazzeri G, Baschiera F, Del Tacca M. Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol 2001;132:73-84. [PMID: 11156563 DOI: 10.1038/sj.bjp.0703766] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
513 Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551-1569. [PMID: 18794772 DOI: 10.3390/molecules13081551] [Cited by in Crossref: 291] [Cited by in F6Publishing: 271] [Article Influence: 22.4] [Reference Citation Analysis]
514 Lopez-Barcons LA, Zhang J, Siriwitayawan G, Burke TG, Perez-Soler R. The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma. Neoplasia 2004;6:457-67. [PMID: 15548354 DOI: 10.1593/neo.04139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
515 Meisenberg C, Gilbert DC, Chalmers A, Haley V, Gollins S, Ward SE, El-Khamisy SF. Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Mol Cancer Ther. 2015;14:575-585. [PMID: 25522766 DOI: 10.1158/1535-7163.mct-14-0762] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 6.1] [Reference Citation Analysis]
516 McQuade RM, Stojanovska V, Donald EL, Rahman AA, Campelj DG, Abalo R, Rybalka E, Bornstein JC, Nurgali K. Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons. Front Physiol 2017;8:391. [PMID: 28642718 DOI: 10.3389/fphys.2017.00391] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
517 Matsuhashi N, Takahashi T, Fujii H, Suetsugu T, Fukada M, Iwata Y, Tokumaru Y, Imai T, Mori R, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Futamura M, Yoshida K. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer. Mol Clin Oncol 2019;11:390-6. [PMID: 31475067 DOI: 10.3892/mco.2019.1899] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
518 Li J, Zhou L, Liu Y, Yang L, Jiang D, Li K, Xie S, Wang X, Wang S. Comprehensive Analysis of Cyclin Family Gene Expression in Colon Cancer. Front Oncol 2021;11:674394. [PMID: 33996604 DOI: 10.3389/fonc.2021.674394] [Reference Citation Analysis]
519 Zhou Y, Zang Y, Yang Y, Xiang J, Chen Z. Candidate genes involved in metastasis of colon cancer identified by integrated analysis. Cancer Med 2019;8:2338-47. [PMID: 30884206 DOI: 10.1002/cam4.2071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
520 Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Invest New Drugs. 2013;31:183-191. [PMID: 22782485 DOI: 10.1007/s10637-012-9853-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
521 Huang Y, Yu H, Lei H, Xie C, Zhong Y. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients. Med Oncol 2014;31:824. [PMID: 24469951 DOI: 10.1007/s12032-013-0824-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
522 Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009;27:1948-55. [PMID: 19255311 DOI: 10.1200/JCO.2008.20.2879] [Cited by in Crossref: 114] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
523 Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics 2012;30:1119-32. [PMID: 23058097 DOI: 10.2165/11597210-000000000-00000] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
524 Yukisawa S, Fujiwara Y, Yamamoto Y, Ueno T, Matsueda K, Kohno A, Suenaga M. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. Br J Radiol 2010;83:850-3. [PMID: 20223904 DOI: 10.1259/bjr/41019720] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
525 Kim G, Jung EJ, Ryu CG, Hwang DY. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer. Yonsei Med J 2013;54:116-22. [PMID: 23225807 DOI: 10.3349/ymj.2013.54.1.116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
526 Aparicio T, Desramé J, Lecomte T, Mitry E, Belloc J, Etienney I, Montembault S, Vayre L, Locher C, Ezenfis J. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer. 2003;89:1439-1444. [PMID: 14562014 DOI: 10.1038/sj.bjc.6601310] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
527 Saunders MP, Valle JW. Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? National Institute of Clinical Excellence. Br J Cancer 2002;86:1667-9. [PMID: 12087447 DOI: 10.1038/sj.bjc.6600369] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
528 Quan Q, Zhong F, Wang X, Chen K, Guo L. PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling. Oncol Res 2019;27:779-88. [PMID: 30841957 DOI: 10.3727/096504018X15442985680348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
529 Maurya DK, Ayuzawa R, Doi C, Troyer D, Tamura M. Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo. J Environ Pathol Toxicol Oncol 2011;30:1-10. [PMID: 21609311 DOI: 10.1615/jenvironpatholtoxicoloncol.v30.i1.10] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
530 Wallace BD, Roberts AB, Pollet RM, Ingle JD, Biernat KA, Pellock SJ, Venkatesh MK, Guthrie L, O'Neal SK, Robinson SJ, Dollinger M, Figueroa E, McShane SR, Cohen RD, Jin J, Frye SV, Zamboni WC, Pepe-Ranney C, Mani S, Kelly L, Redinbo MR. Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. Chem Biol 2015;22:1238-49. [PMID: 26364932 DOI: 10.1016/j.chembiol.2015.08.005] [Cited by in Crossref: 117] [Cited by in F6Publishing: 117] [Article Influence: 19.5] [Reference Citation Analysis]
531 Guérin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, Gaub MP, Guenot D. In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. Mol Med 2012;18:83-94. [PMID: 22033674 DOI: 10.2119/molmed.2011.00120] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
532 Saunders MP, Hogg M, Carrington B, Sjursen AM, Allen J, Beech J, Swindell R, Valle JW. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer. Br J Cancer 2004;91:1447-52. [PMID: 15452550 DOI: 10.1038/sj.bjc.6602173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
533 Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016;9:1899-920. [PMID: 27099521 DOI: 10.2147/OTT.S95101] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
534 Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052-1061; discussion 1061-1064;. [PMID: 15570210 DOI: 10.1097/01.sla.0000145964.08365.01.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
535 Eblen ST. Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol. 2012;83:1063-1072. [PMID: 22248731 DOI: 10.1016/j.bcp.2011.12.041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
536 Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2011;8:332-8. [PMID: 21611115 DOI: 10.7150/ijms.8.332] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
537 Tanaka T, Bai T, Toujima S, Utsunomiya T, Matsuoka T, Kobayashi A, Yamamoto M, Sasaki N, Tanizaki Y, Utsunomiya H, Tanaka J, Yukawa K. Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells. Oncol Rep 2012;27:1292-8. [PMID: 22246465 DOI: 10.3892/or.2012.1628] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
538 Byström P, Björkegren K, Larsson A, Johansson L, Berglund A. Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer. Ups J Med Sci 2009;114:160-4. [PMID: 19736606 DOI: 10.1080/03009730903027172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
539 Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T, Yanaga K. The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 2012;4:324-328. [PMID: 22844378 DOI: 10.3892/ol.2012.722] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
540 Shi M, Ma T, Xi W, Jiang J, Wu J, Zhou C, Yang C, Zhu Z, Zhang J. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. Trials 2020;21:249. [PMID: 32143730 DOI: 10.1186/s13063-020-4194-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
541 Kim H, Baek SE, Moon J, Roh YH, Lee N, Cho A. Increased hepatic FDG uptake on PET/CT in hepatic sinusoidal obstructive syndrome. Oncotarget 2016;7:69024-31. [PMID: 27602584 DOI: 10.18632/oncotarget.11816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
542 Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34. [PMID: 28349281 DOI: 10.1007/s10147-017-1101-6] [Cited by in Crossref: 400] [Cited by in F6Publishing: 364] [Article Influence: 100.0] [Reference Citation Analysis]
543 Mendoza-Rodríguez MG, Sánchez-Barrera CÁ, Callejas BE, García-Castillo V, Beristain-Terrazas DL, Delgado-Buenrostro NL, Chirino YI, León-Cabrera SA, Rodríguez-Sosa M, Gutierrez-Cirlos EB, Pérez-Plasencia C, Vaca-Paniagua F, Meraz-Ríos MA, Terrazas LI. Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis. Int J Mol Sci 2020;21:E2130. [PMID: 32244885 DOI: 10.3390/ijms21062130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
544 Chan KK, Wong B, Siu LL, Straus SE, Chang J, Berry SR. Less than ideal: how oncologists practice with limited drug access. J Oncol Pract 2012;8:190-5. [PMID: 22942815 DOI: 10.1200/JOP.2011.000337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
545 Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011;20:384-99. [PMID: 21907928 DOI: 10.1016/j.ccr.2011.08.013] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 8.9] [Reference Citation Analysis]
546 Paré-Brunet L, Sebio A, Salazar J, Berenguer-Llergo A, Río E, Barnadas A, Baiget M, Páez D. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Pharmacogenomics J 2015;15:397-404. [PMID: 25707392 DOI: 10.1038/tpj.2015.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
547 Ding HH, Wu WD, Jiang T, Cao J, Ji ZY, Jin JH, Wang JJ, Song WF, Wang LW. Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). Tumour Biol 2015;36:3361-9. [PMID: 25534239 DOI: 10.1007/s13277-014-2970-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
548 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Marusasa T, Hashiguchi T, Uchida T, Sakuyama N, Sato T, Kishine K, Futagawa S, Nagaoka I. Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer. Oncol Lett 2011;2:309-13. [PMID: 22866082 DOI: 10.3892/ol.2011.251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
549 Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42. [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z] [Cited by in Crossref: 282] [Cited by in F6Publishing: 268] [Article Influence: 141.0] [Reference Citation Analysis]
550 Kambe M, Kikuchi H, Gamo M, Yoshioka T, Ohashi Y, Kanamaru R. Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. Int J Clin Oncol 2012;17:150-4. [PMID: 21786211 DOI: 10.1007/s10147-011-0272-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
551 Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057-1077. [PMID: 17530336 DOI: 10.1007/s11605-006-0061-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 136] [Article Influence: 10.8] [Reference Citation Analysis]
552 Wang D, Chen Y, Fang H, Zheng L, Li Y, Yang F, Xu Y, Du L, Zhou BS, Li H. Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5-Fluorouracil. J Cell Mol Med 2018;22:6202-12. [PMID: 30255549 DOI: 10.1111/jcmm.13907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
553 Reese ES, Onukwugha E, Hanna N, Seal BS, Mullins CD. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Med 2013;2:907-15. [PMID: 24403264 DOI: 10.1002/cam4.143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
554 Zhang Y, Liu Y, Ye Y, Shen D, Zhang H, Huang H, Li S, Wang S, Ren J. Quantitative proteome analysis of colorectal cancer-related differential proteins. J Cancer Res Clin Oncol 2017;143:233-41. [PMID: 27659785 DOI: 10.1007/s00432-016-2274-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
555 Zhu GQ, You J, Shi KQ, He SY, Wang LR, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases. Medicine (Baltimore) 2015;94:e379. [PMID: 25569666 DOI: 10.1097/MD.0000000000000379] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
556 刘慧龙, 李志宇, 刘彦芳, 李红英, 于忠和. 伊立替康治疗结直肠癌相关胆碱能综合征89例. 世界华人消化杂志 2012; 20(11): 975-979 [DOI: 10.11569/wcjd.v20.i11.975] [Reference Citation Analysis]
557 Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D. Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Sci Rep 2017;7:10426. [PMID: 28874797 DOI: 10.1038/s41598-017-11048-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
558 Katalinic D, Santek F, Juretic A, Skegro D, Plestina S. Gastroenteropancreatic neuroendocrine tumour arising in Meckel's diverticulum coexisting with colon adenocarcinoma. World J Surg Oncol 2014;12:358. [PMID: 25427657 DOI: 10.1186/1477-7819-12-358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
559 Nguyen-Khac E, Lobry C, Chatelain D, Fuks D, Joly JP, Brevet M, Tramier B, Mouly C, Hautefeuille V, Chauffert B, Regimbeau JM. A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. Int J Hepatol 2013;2013:314868. [PMID: 23533786 DOI: 10.1155/2013/314868] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
560 Kornmann M, Link KH, Galuba I, Ott K, Schwabe W, Häusler P, Scholz P, Sträter J, Polat S, Leibl B, Kettner E, Schlichting C, Baumann W, Schramm H, Hecker U, Ridwelski K, Vogt JH, Zerbian KU, Schütze F, Kreuser ED, Behnke D, Beger HG. Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J Gastrointest Surg 2002;6:331-7. [PMID: 12022983 DOI: 10.1016/s1091-255x(02)00018-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
561 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
562 Maeda H, Hazama S, Shavkat A, Okamoto K, Oba K, Sakamoto J, Takahashi K, Oka M, Nakamura D, Tsunedomi R, Okayama N, Mishima H, Kobayashi M. Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations. Mol Diagn Ther 2014;18:333-42. [PMID: 24453052 DOI: 10.1007/s40291-014-0083-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
563 Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283 [PMID: 19750570 DOI: 10.3748/wjg.15.4278] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
564 Jiang X, Li Q, Zhang S, Song C, Zheng P. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther 2019;12:1059-70. [PMID: 30799935 DOI: 10.2147/OTT.S192290] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
565 Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol. 2010;69:58-66. [PMID: 20078613 DOI: 10.1111/j.1365-2125.2009.03556.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
566 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. [Therapy response of liver tumors after selective internal radiation therapy]. Radiologe. 2008;48:839-849. [PMID: 18766324 DOI: 10.1007/s00117-008-1730-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
567 Jefford M, Michael M, Rosenthal MA, Davis ID, Green M, McClure B, Smith J, Waite B, Zalcberg J. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer. Invest New Drugs 2004;22:185-92. [PMID: 14739668 DOI: 10.1023/B:DRUG.0000011796.20332.a9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
568 Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003;7:1082-1088. [PMID: 14675719 DOI: 10.1097/00000658-200205000-00015] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 8.1] [Reference Citation Analysis]
569 Watkins DJ, Chau I, Cunningham D, Mudan SS, Karanjia N, Brown G, Ashley S, Norman AR, Gillbanks A. Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. Br J Cancer 2010;102:255-61. [PMID: 20087355 DOI: 10.1038/sj.bjc.6605508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
570 Siveen KS, Raza A, Ahmed EI, Khan AQ, Prabhu KS, Kuttikrishnan S, Mateo JM, Zayed H, Rasul K, Azizi F, Dermime S, Steinhoff M, Uddin S. The Role of Extracellular Vesicles as Modulators of the Tumor Microenvironment, Metastasis and Drug Resistance in Colorectal Cancer. Cancers (Basel) 2019;11:E746. [PMID: 31146452 DOI: 10.3390/cancers11060746] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
571 Was H, Czarnecka J, Kominek A, Barszcz K, Bernas T, Piwocka K, Kaminska B. Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. Cancer Biol Ther 2018;19:63-75. [PMID: 29053388 DOI: 10.1080/15384047.2017.1385675] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
572 Feliu J, Salud A, Escudero P, Lopez-Gómez L, Bolaños M, Galán A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, González-Barón M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969-75. [PMID: 16552438 DOI: 10.1038/sj.bjc.6603047] [Cited by in Crossref: 82] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
573 Slevin M, Payne S. New treatments for colon cancer. BMJ 2004;329:124-6. [PMID: 15258046 DOI: 10.1136/bmj.329.7458.124] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
574 Artaç M, Coşkun HŞ, Dane F, Karabulut B, Korkmaz L, Karaağaç M, Çabuk D, Karabulut S, Faruk Aykan N, Doruk H, Avcı N, Turhal NS. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. J Gastrointest Cancer 2016;47:264-72. [PMID: 27126591 DOI: 10.1007/s12029-016-9823-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
575 Shepelytskyi Y, Fox MS, Davenport K, Li T, Albert MS, Davenport E. In-Vivo Retention of 5-Fluorouracil Using 19F Magnetic Resonance Chemical Shift Imaging in Colorectal Cancer in a Murine Model. Sci Rep 2019;9:13244. [PMID: 31519979 DOI: 10.1038/s41598-019-49716-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
576 Riera P, Artigas-Baleri A, Salazar J, Sebio A, Virgili AC, Arranz MJ, Páez D. ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Front Pharmacol 2020;11:973. [PMID: 32695000 DOI: 10.3389/fphar.2020.00973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
577 Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol 2015;12:607-19. [PMID: 26215044 DOI: 10.1038/nrclinonc.2015.129] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 15.2] [Reference Citation Analysis]
578 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012;17:1-29. [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2] [Cited by in Crossref: 491] [Cited by in F6Publishing: 477] [Article Influence: 49.1] [Reference Citation Analysis]
579 Li P, Zhang X, Wang L, Du L, Yang Y, Liu T, Li C, Wang C. lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer. Mol Ther Nucleic Acids 2017;8:356-69. [PMID: 28918035 DOI: 10.1016/j.omtn.2017.07.007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 17.5] [Reference Citation Analysis]
580 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
581 Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005;28:417-33. [PMID: 15853443 DOI: 10.2165/00002018-200528050-00005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
582 Cecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 2021;127:1417-24. [PMID: 33351187 DOI: 10.1002/cncr.33379] [Reference Citation Analysis]
583 Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Interaction of tumour biology and tumour burden in determining outcome after hepatic resection for colorectal metastases. HPB (Oxford) 2010;12:84-93. [PMID: 20495651 DOI: 10.1111/j.1477-2574.2009.00127.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
584 Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K, Hirakawa K. The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. BMC Cancer 2015;15:347. [PMID: 25934494 DOI: 10.1186/s12885-015-1375-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
585 Pellino G, Gallo G, Pallante P, Capasso R, De Stefano A, Maretto I, Malapelle U, Qiu S, Nikolaou S, Barina A, Clerico G, Reginelli A, Giuliani A, Sciaudone G, Kontovounisios C, Brunese L, Trompetto M, Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018;2018:2397863. [PMID: 30008744 DOI: 10.1155/2018/2397863] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
586 Liu X, Cao Z, Mendoza J, Vardeman D, Giovanella B. Correlation between the sensitivity of tumors to treatment with CZ48 and local concentrations of the active metabolite CPT within the tumors. Biomed Rep 2013;1:202-6. [PMID: 24648919 DOI: 10.3892/br.2013.55] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
587 Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008;99:83-89. [PMID: 18577988 DOI: 10.1038/sj.bjc.6604439] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 9.6] [Reference Citation Analysis]
588 Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 2015;76:925-32. [PMID: 26370544 DOI: 10.1007/s00280-015-2850-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
589 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Reference Citation Analysis]
590 Huy TL, Bui MH, Dinh TC, Xuyen HTH. Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer. Open Access Maced J Med Sci 2019;7:4244-9. [PMID: 32215071 DOI: 10.3889/oamjms.2019.368] [Reference Citation Analysis]
591 Pesenti C, Gusella M, Sirchia SM, Miozzo M. Germline oncopharmacogenetics, a promising field in cancer therapy. Cell Oncol (Dordr) 2015;38:65-89. [PMID: 25573079 DOI: 10.1007/s13402-014-0214-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
592 Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002;86:1677-83. [PMID: 12087449 DOI: 10.1038/sj.bjc.6600204] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
593 Alonso S, Saltz L. The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer. Ann Surg Oncol 2021;28:995-1001. [PMID: 33230749 DOI: 10.1245/s10434-020-09375-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
594 Zhang Y, Jiang HY, Wei Y, Song B. Sinusoidal obstruction syndrome: A systematic review of etiologies, clinical symptoms, and magnetic resonance imaging features. World J Clin Cases 2019; 7(18): 2746-2759 [PMID: 31616690 DOI: 10.12998/wjcc.v7.i18.2746] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
595 Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008;99:1239-1245. [PMID: 18797458 DOI: 10.1038/sj.bjc.6604673] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
596 Liu Y, DU F, Zhao Q, Jin J, Ma X, Li H. Acquisition of 5-fluorouracil resistance induces epithelial-mesenchymal transitions through the Hedgehog signaling pathway in HCT-8 colon cancer cells. Oncol Lett 2015;9:2675-9. [PMID: 26137127 DOI: 10.3892/ol.2015.3136] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
597 Peinert S, Grothe W, Stein A, Müller LP, Ruessel J, Voigt W, Schmoll HJ, Arnold D. Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Ther Adv Med Oncol 2010;2:161-74. [PMID: 21789132 DOI: 10.1177/1758834010365061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
598 Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006;95:131-8. [PMID: 16835584 DOI: 10.1038/sj.bjc.6603233] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
599 Suenaga M, Mizunuma N, Chin K, Matsusaka S, Shinozaki E, Oya M, Ueno M, Yamaguchi T, Muto T, Konishi F, Hatake K. Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today 2009;39:27-31. [PMID: 19132464 DOI: 10.1007/s00595-008-3843-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
600 Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13(28): 3806-3815 [PMID: 17657834 DOI: 10.3748/wjg.v13.i28.3806] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
601 Sheikh HY, Valle JW, Waddell T, Palmer K, Wilson G, Sjursen A, Craven O, Swindell R, Saunders MP. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. Br J Cancer 2008;99:577-83. [PMID: 18682717 DOI: 10.1038/sj.bjc.6604499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
602 Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D’Argento E, Trigila N, Astone A, Pozzo C. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035-1039. [PMID: 17895897 DOI: 10.1038/sj.bjc.6603988] [Cited by in Crossref: 95] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
603 Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, Haller DG, O'Dwyer PJ. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer. 2005;92:1846-1849. [PMID: 15870719 DOI: 10.1038/sj.bjc.6602569] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
604 Matsumoto Y, Saito M, Saito K, Kanke Y, Watanabe Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Kumamoto K, Ohki S, Takenoshita S. Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis. Oncol Lett 2018;15:2188-94. [PMID: 29434924 DOI: 10.3892/ol.2017.7555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
605 Manne U, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark. 2010;9:235-265. [PMID: 22112479 DOI: 10.3233/cbm-2011-0160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
606 Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, Wu L, Bosenberg M, Muzumdar MD, Khan S, Lu Q, Yan Q, Lu J. 5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING. EMBO J 2021;40:e106065. [PMID: 33615517 DOI: 10.15252/embj.2020106065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
607 Delord JP, Bennouna J, Artru P, Perrier H, Husseini F, Desseigne F, François E, Faroux R, Smith D, Piedbois P, Naman H, Douillard JY, Bugat R. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. Br J Cancer 2007;97:297-301. [PMID: 17637682 DOI: 10.1038/sj.bjc.6603889] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
608 Uchida K, Hayashi K, Kuramochi H, Nakajima G, Inoue Y, Yamamoto M. Combination therapy of S-1 and CDDP for patients with colorectal cancer. J Cancer Res Clin Oncol 2007;133:841-6. [PMID: 17479286 DOI: 10.1007/s00432-007-0226-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
609 Ribeiro IB, de Moura DTH, Thompson CC, de Moura EGH. Acute abdominal obstruction: Colon stent or emergency surgery? An evidence-based review. World J Gastrointest Endosc 2019; 11(3): 193-208 [PMID: 30918585 DOI: 10.4253/wjge.v11.i3.193] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
610 Meijerink MR, Puijk RS, van Tilborg AAJM, Henningsen KH, Fernandez LG, Neyt M, Heymans J, Frankema JS, de Jong KP, Richel DJ, Prevoo W, Vlayen J. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Cardiovasc Intervent Radiol. 2018;41:1189-1204. [PMID: 29666906 DOI: 10.1007/s00270-018-1959-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 21.0] [Reference Citation Analysis]
611 Sag AA, Selcukbiricik F, Mandel NM. Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol 2016; 22(11): 3127-3149 [PMID: 27003990 DOI: 10.3748/wjg.v22.i11.3127] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
612 Rapic S, Vangestel C, Elvas F, Verhaeghe J, den Wyngaert TV, Wyffels L, Pauwels P, Staelens S, Stroobants S. Evaluation of [18F]CP18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology. Mol Imaging Biol 2017;19:560-9. [PMID: 28050749 DOI: 10.1007/s11307-016-1037-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
613 Mitsuyama Y, Shiba H, Haruki K, Fujiwara Y, Furukawa K, Iida T, Hayashi T, Ogawa M, Ishida Y, Misawa T, Kashiwagi H, Yanaga K. Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis. Oncol Lett 2012;3:767-71. [PMID: 22740990 DOI: 10.3892/ol.2012.574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
614 Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-57; discussion 657-8. [PMID: 15383792 DOI: 10.1097/01.sla.0000141198.92114.f6] [Cited by in Crossref: 236] [Cited by in F6Publishing: 493] [Article Influence: 13.9] [Reference Citation Analysis]
615 Gorbunova V, Beck JT, Hofheinz RD, Garcia-Alfonso P, Nechaeva M, Cubillo Gracian A, Mangel L, Elez Fernandez E, Deming DA, Ramanathan RK, Torres AH, Sullivan D, Luo Y, Berlin JD. A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Br J Cancer 2019;120:183-9. [PMID: 30531832 DOI: 10.1038/s41416-018-0343-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
616 Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol 2009;1:55-68. [PMID: 21789113 DOI: 10.1177/1758834009343302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
617 Toden S, Okugawa Y, Jascur T, Wodarz D, Komarova NL, Buhrmann C, Shakibaei M, Boland CR, Goel A. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis 2015;36:355-67. [PMID: 25653233 DOI: 10.1093/carcin/bgv006] [Cited by in Crossref: 118] [Cited by in F6Publishing: 117] [Article Influence: 19.7] [Reference Citation Analysis]
618 Troiani T, Martinelli E, Morgillo F, Capasso A, Nappi A, Sforza V, Ciardiello F. Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? Ther Adv Med Oncol 2013;5:51-72. [PMID: 23323147 DOI: 10.1177/1758834012462462] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
619 Kurniali PC, Hrinczenko B, Al-Janadi A. Management of locally advanced and metastatic colon cancer in elderly patients. World J Gastroenterol 2014; 20(8): 1910-1922 [PMID: 24616568 DOI: 10.3748/wjg.v20.i8.1910] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
620 Gill S, Goldberg RM. New developments in therapy for colorectal cancer. Curr Oncol Rep 2003;5:183-91. [PMID: 12667415 DOI: 10.1007/s11912-003-0109-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
621 Louvet C, André T, Gamelin E, Hebbar M, Mabro M, Bennamoun M, Rassam H, de Gramont A. Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer. J Oncol 2010;2010:785934. [PMID: 20396391 DOI: 10.1155/2010/785934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
622 Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138:65-72. [PMID: 21960318 DOI: 10.1007/s00432-011-1061-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
623 Bandrés E, Zárate R, Ramirez N, Abajo A, Bitarte N, García-Foncillas J. Pharmacogenomics in colorectal cancer: The first step for individualized-therapy. World J Gastroenterol 2007; 13(44): 5888-5901 [PMID: 17990354 DOI: 10.3748/wjg.v13.i44.5888] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
624 Wahba HA, El-Hadaad HA, Roshdy S. Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. J Gastrointest Cancer 2012;43:467-71. [PMID: 22147447 DOI: 10.1007/s12029-011-9350-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
625 Huynh N, Shulkes A, Baldwin G, He H. Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer. Cancer Biol Ther 2016;17:813-23. [PMID: 27260988 DOI: 10.1080/15384047.2016.1195045] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
626 Cross-Knorr S, Lu S, Perez K, Guevara S, Brilliant K, Pisano C, Quesenberry PJ, Resnick MB, Chatterjee D. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. BMC Cancer 2013;13:463. [PMID: 24098947 DOI: 10.1186/1471-2407-13-463] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
627 Wang L, Wang Y, Lu Y, Zhang Q, Qu X. Heterozygous deletion of ATG5 in Apc(Min/+) mice promotes intestinal adenoma growth and enhances the antitumor efficacy of interferon-gamma. Cancer Biol Ther. 2015;16:383-391. [PMID: 25695667 DOI: 10.1080/15384047.2014.1002331] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
628 Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87:393-399. [PMID: 12177775 DOI: 10.1038/sj.bjc.6600467] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 4.5] [Reference Citation Analysis]
629 O'Malley G, Heijltjes M, Houston AM, Rani S, Ritter T, Egan LJ, Ryan AE. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response? Oncotarget 2016;7:60752-74. [PMID: 27542276 DOI: 10.18632/oncotarget.11354] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
630 Recchia F, Saggio G, Nuzzo A, Lalli A, Lullo LD, Cesta A, Rea S. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer. 2004;91:1442-1446. [PMID: 15467766 DOI: 10.1038/sj.bjc.6602194] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
631 Palshof JA, Cederbye CN, Høgdall EVS, Poulsen TS, Linnemann D, Nygaard SB, Stenvang J, Christensen IJ, Jensen BV, Pfeiffer P, Brünner N, Yilmaz M, Viuff BM, Nielsen DL. ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. Int J Mol Sci 2020;21:E5027. [PMID: 32708825 DOI: 10.3390/ijms21145027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
632 Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor MD, Chaves M. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer. 2014;14:656. [PMID: 25197016 DOI: 10.1186/1471-2407-14-656] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
633 Moehler M, Frings C, Mueller A, Gockel I, Schimanski CC, Biesterfeld S, Galle PR, Holtmann MH. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol 2008; 14(26): 4156-4167 [PMID: 18636661 DOI: 10.3748/wjg.14.4156] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
634 Xie T, Geng J, Wang Y, Wang L, Huang M, Chen J, Zhang K, Xue L, Liu X, Mao X, Chen Y, Wang Q, Dai T, Ren L, Yu H, Wang R, Chen L, Chen C, Chu X. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget 2017;8:8574-89. [PMID: 28051999 DOI: 10.18632/oncotarget.14351] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
635 Ligabue A, Marverti G, Liebl U, Myllykallio H. Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression. PLoS One 2012;7:e47318. [PMID: 23056627 DOI: 10.1371/journal.pone.0047318] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
636 Thirion P, Piedbois P, Buyse M, O'Dwyer PJ, Cunningham D, Man A, Greco FA, Colucci G, Köhne CH, Di Constanzo F, Piga A, Palmeri S, Dufour P, Cassano A, Pajkos G, Pensel RA, Aykan NF, Marsh J, Seymour MT; Meta-Analysis Group in Cancer. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. Br J Cancer 2001;84:611-20. [PMID: 11237380 DOI: 10.1054/bjoc.2000.1669] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
637 Wang DS, Hu MT, Wang ZQ, Ren C, Qiu MZ, Luo HY, Jin Y, Fong WP, Wang SB, Peng JW, Zou QF, Tan Q, Wang FH, Li YH. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open 2021;4:e215250. [PMID: 33835174 DOI: 10.1001/jamanetworkopen.2021.5250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
638 Twelves CJ, Cassidy J. Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? Br J Cancer 2002;86:1670-6. [PMID: 12087448 DOI: 10.1038/sj.bjc.6600341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
639 Shimada H, Tanaka K, Endou I, Ichikawa Y. Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg. 2009;394:973-983. [PMID: 19582473 DOI: 10.1007/s00423-009-0530-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
640 Wagner S, Beger NT, Matschos S, Szymanski A, Przybylla R, Bürtin F, Prall F, Linnebacher M, Mullins CS. Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:4717. [PMID: 34572946 DOI: 10.3390/cancers13184717] [Reference Citation Analysis]
641 Shimura T, Kataoka H, Hirata Y, Mizushima T, Murakami K, Mabuchi M, Mizoshita T, Kubota E, Tanida S, Kamiya T, Joh T. Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy. J Gastrointest Cancer 2011;42:68-72. [PMID: 20563895 DOI: 10.1007/s12029-010-9176-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
642 Grande R, Gemma D, Sperduti I, Gelibter A, Giampaolo MA, Trombetta G, Nelli F, Gamucci T. Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained? Springerplus 2013;2:185. [PMID: 23667824 DOI: 10.1186/2193-1801-2-185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
643 Folprecht G. [Current medicinal treatment of metastasized colorectal carcinoma]. Chirurg. 2010;81:507-515. [PMID: 20574792 DOI: 10.1007/s00104-010-1892-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
644 Vaugier L, Mirabel X, Martel-Lafay I, Racadot S, Carrie C, Vendrely V, Mahé MA, Senellart H, Raoul JL, Campion L, Rio E. Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. Cancers (Basel) 2021;13:E248. [PMID: 33440832 DOI: 10.3390/cancers13020248] [Reference Citation Analysis]
645 Ogata Y, Tanaka T, Akagi Y, Ishibashi N, Tsuji Y, Matono K, Isobe M, Sueyoshi S, Kaibara A, Shirouzu K. Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer. Clin Med Insights Oncol. 2013;7:21-30. [PMID: 23439317 DOI: 10.4137/CMO.S10769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
646 Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: Where to fit the target? World J Gastroenterol 2014; 20(8): 1993-2004 [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
647 Jang HJ, Kim BJ, Kim JH, Kim HS. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget. 2017;8:73009-73016. [PMID: 29069844 DOI: 10.18632/oncotarget.20314] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
648 Gao Y, Li W, Chen J, Wang X, Lv Y, Huang Y, Zhang Z, Xu F. Pharmacom